

 Open access • Posted Content • DOI:10.1101/2020.01.24.918656

BACTrace a new tool for retrograde tracing of neuronal circuits — [Source link](#)

Sebastian Cachero, Marina Gkantia, Alexander Shakeel Bates, Shahar Frechter ...+9 more authors

Institutions: Laboratory of Molecular Biology, Imperial College London, University of Manchester, University College London ...+1 more institutions

Published on: 25 Jan 2020 - [bioRxiv](#) (Cold Spring Harbor Laboratory)

Topics: Connectomics and Retrograde tracing

Related papers:

- [Retrograde fluorescent labeling allows for targeted extracellular single-unit recording from identified neurons in vivo.](#)
- [Multisteped optogenetics connects neurons and behavior](#)
- [An optogenetic toolbox for unbiased discovery of functionally connected cells in neural circuits](#)
- [Genetically Targeted Optical Electrophysiology in Intact Neural Circuits](#)
- [Integrating anatomy and function for zebrafish circuit analysis.](#)

Share this paper:    

View more about this paper here: <https://typeset.io/papers/bactrace-a-new-tool-for-retrograde-tracing-of-neuronal-4qhphcx6ey>

BACTrace a new tool for retrograde tracing of neuronal circuits

Sebastian Cachero^{1,*}, Marina Gkantia¹, Alexander S. Bates¹, Shahar Frechter¹, Laura Blackie^{1,3}, Amy McCarthy^{1,4}, Ben Sutcliffe¹, Alessio Strano^{1,5}, Yoshinori Aso², Gregory S.X.E. Jefferis^{1,*}

¹ *Neurobiology Division, MRC Laboratory of Molecular Biology, Cambridge, UK*

² *Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, United States*

³ *Current address: MRC London Institute of Medical Sciences, Imperial College London, UK*

⁴ *Current address: Cancer Research UK Manchester Institute, The University of Manchester, UK*

⁵ *Current address: Department of Cancer and Developmental Biology & Zayed Centre for Research into Rare Disease in Children, University College London, UK*

* Correspondence: scachero@mrc-lmb.cam.ac.uk, jefferis@mrc-lmb.cam.ac.uk

Abstract

New tools and techniques have enabled many key advances in our understanding of the brain. To elucidate circuit function, it is necessary to identify, record from and manipulate networks of connected neurons. Here we present BACTrace (Botulinum Activated Tracer), the first fully genetically encoded, retrograde, transsynaptic labelling system. BACTrace is based on *C. botulinum* neurotoxin A, Botox, which we have engineered to act as a Trojan horse that jumps retrogradely between neurons to activate an otherwise silent transcription factor. We validate BACTrace at three connections in the *Drosophila* olfactory system and show that it enables electrophysiological recordings of connected neurons. Finally, in a challenging circuit with highly divergent connections, we used Electron Microscopy connectomics to show that BACTrace correctly identifies 12 out of 16 connections.

12 **1. Introduction**

13 The development of genetic tools to elucidate connectivity and manipulate neurons and circuits has
14 been key to advancing our understanding of how the brain works. Increasingly these tools are being
15 used to study diseases of the nervous system and develop effective treatments [31, 57].

16 In the context of circuit research, the ability to identify and manipulate pre- or post-synaptic cells to
17 neurons of interest is of crucial importance. For example, if genetic drivers are available for sensory
18 neurons in the skin then one might want to label downstream, post-synaptic cells in the nerve cord.
19 Conversely, when studying motor circuits, genetic drivers for motor neurons might be available and
20 revealing upstream, pre-synaptic cells will be appropriate. Tools to label downstream neurons (e.g. for
21 “walking” from sensory input towards motor-outputs as in the first example) are called anterograde,
22 while retrograde tools reveal the input neurons to a given population.

23 *Drosophila melanogaster* is a key model organisms to study the genetic and circuit basis of animal
24 behaviour (e.g. see [62, 15]). The fly has a rich behavioural repertoire encoded in a relatively small
25 nervous system. This numerical simplicity is paired with extensive collections of genetic reagents,
26 both to investigate gene function (e.g. mutant and RNAi collections) and to label and manipulate
27 most neuronal classes (using the orthogonal expression systems Gal4, LexA, QF and their split versions
28 [4, 45, 30, 58]). While these reagents offer excellent genetic access to neurons, until recently the
29 fly lacked tools to map synaptic connections between neurons. This has recently changed with the
30 development of electron microscopy methods to map connections in larval [38] and adult [63] brains.
31 Furthermore, two genetically encoded systems for anterograde tracing: *trans*-Tango [54] and TRACT
32 [22] have recently been developed. Despite these important additions to the experimental toolbox, a
33 retrograde labelling system is still missing. Rabies virus and its modifications constitute the most notable
34 examples of retrograde transsynaptic tools [31]. While in mice rabies has been used to great success,
35 its applicability to flies is far from simple, both because of the experimental difficulties of delivering
36 viruses via brain injections and because the virus neurotropism may not extend to flies.

37 We now introduce BAcTrace (Botulinum Activated Tracer), a fully genetically encoded retrograde
38 tracing tool for *Drosophila*. We first established the system in tissue culture to demonstrate its viability.
39 Then we implemented and refined BAcTrace in flies, showing that it can reveal the connectivity between

40 olfactory Projection Neurons (PNs) and 3 different classes of presynaptic neurons: Olfactory Receptor
41 Neurons, Kenyon Cells of the Mushroom Bodies and Lateral Horn Neurons. BAcTrace provides a
42 powerful new way to test connectivity and manipulate components in circuits with high sensitivity and
43 specificity.

44 2. Results

45 2.1. System design

46 Transsynaptic tools must induce labelling in connected neurons with high signal to noise ratio avoiding
47 false positives. Labelling must depend on some form of communication between connected cells, either
48 by transfer of material between them or through contact-based signal induction. Rabies virus falls
49 within the first category: infected neurons make new viral particles which spread via synaptic contacts
50 and once in the cytosol of connected neurons get amplified, strongly labelling them. *trans*-Tango and
51 TRACT belong to the contact-based category; pre-synaptic neurons make a ligand that binds a receptor
52 in post-synaptic partners triggering a conformational change that eventually activates a transcription
53 factor.

54 To reveal neuronal connectivity in the fly brain, we designed BAcTrace, a novel transsynaptic labelling
55 system which is fully genetically encoded and, in contrast to contact based systems, shares two key
56 feature of rabies: 1. labelling is triggered by protein transfer between connected neurons and 2. this
57 transfer is followed by a signal amplification step. We reasoned that this design could allow increases
58 in sensitivity without compromising signal-to-noise ratio. At the core of our system sits a neuronal
59 trojan horse, *Clostridium botulinum* neurotoxin A1 (BoNT/A). BoNT/A is well suited to synthetic
60 biology because it is a modular protein (Fig. 1A and S1) with a well-studied mechanism of action
61 (Fig. S2). BoNT/A is made as a single polypeptide that gets cleaved by proteases generating a Light
62 Chain (LC) and a Heavy Chain (HC) (Fig. 1A). During intoxication in vertebrates, the receptor binding
63 domain (RBD), located in the C-terminal half of the HC, enables enrichment on neuronal membranes
64 by interacting with a neuronal specific lipid (polysialoganglioside GT1b). Upon neurotransmitter vesicle
65 fusion the RBD gains access to the vesicle lumen and binds with high affinity to a second partner,
66 synaptic protein SV2 [14]. When the vesicle is recycled and acidified, the translocation domain (TD)




Figure 1: **System design.** (A) Molecular structure of BoNT/A (3BTA, [29]). Toxin domains are coloured red (protease), yellow (belt), green (Translocation, TD) and blue (Receptor Binding, RBD). (B) Retargeted BoNT/A: the RBD from (A) has been replaced by an anti-GFP nanobody (blue). Also shown in green is the bound GFP (3OGO, [28]). CD2 and Synaptobrevin targeting the toxin and the GFP to the plasma and neurotransmitter vesicle membranes are also indicated. (C) Schematic showing the three steps leading to the labelling. (D) Schematic of the proteins and molecular mechanisms mediating each step in (C). All colours are as in (B) except pink sections in BoNT/A::GFPnb::CD2 which indicate TEV cleavage sites engineered into the toxin for its membrane release by TEV.

67 undergoes a conformational change injecting the LC across the vesicle membrane. The LC is a protease
 68 highly specific for the human protein SNAP25 (hSNAP25) and once in the cytosol it cleaves its target,
 69 preventing further neurotransmitter release [35, 44].

70 In BAcTrace BoNT/A is expressed in post-synaptic “Donor” neurons and transferred, similarly to ra-
 71 bies, to connected pre-synaptic “Receiver” cells to trigger expression of an effector gene. By virtue of
 72 *Botulinum* neurotoxin intrinsic mechanism of action our system works retrogradely, opposite to the flow
 73 of information. BAcTrace can be broken down into three steps (Fig. 1C,D): 1. Toxin release from
 74 Donor neurons into the synaptic cleft, 2. Targeting to neurotransmitter vesicles and escape into the
 75 cytosol and 3. Readout in the form of activating effector gene expression.

76 During step 1 (Fig. 1D) BoNT/A is made in Donor neurons attached to the extracellular portion of
 77 a transmembrane protein (CD2) and the Tobacco Etch Protease (TEV), a protease previously used in
 78 flies [40], is made in Receiver neurons attached to the extracellular portion of a second transmembrane

79 protein. At synapses both proteins interact and TEV cleaves two recognition sites, releasing the toxin
80 from the membrane, and allowing separation of the LC and HC after translocation (Fig. 1B,D). Because
81 flies lack BoNT/A vertebrate receptor SV2, we switched the RBD for a single-chain anti-GFP nanobody
82 (GFPnb) [28] to create BoNT/A::GFPnb::CD2 (Fig. 1B and S3). This modified toxin is targeted to
83 neurotransmitter vesicles of Receiver neurons that express a Synaptobrevin::GFP fusion, oriented with
84 GFP inside the vesicle. This re-targeting also makes the toxin safe, since it can no longer bind to
85 vertebrate neurons. At the end of step 2, the toxin LC protease enters the pre-synaptic terminal.

86 As a readout we made a toxin sensor by linking a QF2 transcription factor [46] to a *Drosophila* Syntaxin
87 molecule via amino acids 141-206 of hSNAP25 [60] (QF2::hSNAP25::Syx). Syntaxin targets the sensor
88 to the synaptic membrane, so that QF2 cannot activate transcription. However cytosolic LC will release
89 QF2, triggering expression of a QUAS-reporter transgene. BoNT/A LC is highly specific and it has been
90 shown to not cleave *Drosophila* SNAP25 (dSNAP25) [60], so toxin expression should not be harmful
91 to flies.

92 2.2. BAcTrace is active in *Drosophila* cells

93 We started by testing, step by step, the feasibility of our approach in *Drosophila* tissue culture S2 cells.
94 To establish that the retargeted BoNT/A::GFPnb-GFP receptor pair could mediate toxin transfer we
95 expressed and purified BoNT/A::GFPnb from bacteria. We added the purified toxin to S2 cells rendered
96 sensitive by expression of a hTfR::GFP receptor which cycles between the plasma membrane and a low
97 pH compartment ([20] and supplemental text 7.1.1). The cells were also transfected with a FLAG tagged
98 hSNAP25, a simple toxin sensor (see Fig. 2A). Cleavage of Flag::hSNAP25 was measured by western
99 blot as a small shift of 0.9kDa (9 amino acids). Fig. 2B shows that all tested toxin concentrations
100 induced efficient cleavage (see also Fig. S4A and supplemental text 7.1.2). Furthermore, hTfR::GFP
101 was strictly required for BoNT/A::GFPnb to induce hSNAP25 cleavage ('No receptor' lanes in Fig.
102 2B).

103 We also tested the sensor to be used in flies. QF2::hSNAP25::Syx can indeed be cleaved by BoNT/A::GFPnb
104 (Fig. 2B) and the released QF2 induces Tomato expression, confirming that function of QF2 as a tran-
105 scription factor is not inhibited by the 62 amino acids of hSNAP25 left on its C-terminus. Unexpectedly,
106 the QF2::hSNAP25::Syx cleavage product accumulates less than that of hSNAP25. This may be due




Figure 2: **Testing BAcTrace in tissue culture.** (A) Schematic of transgenes and tissue culture experimental outline used to test *E. coli* produced toxin. (B) Western blot analysis of S2 cell extracts after transfection and incubation with toxin made in bacteria. Empty arrowheads indicate un-cleaved and solid arrowheads indicate cleaved toxin sensors. Toxin concentrations (nM) in each lane are: 0, 1.7, 3.4, 6.9, 14, 0, 1.7, 3.4, 6.9 and 14. Smaller band in Tomato::HA panels is a degradation C-terminal fragment. (C) Schematic of cell mixing experiments to test toxin produced in insect cells. (D) Western blot analysis of S2 cell extracts from cell mixing experiments. Conditions marked with * correspond to those from panel (C). Epitopes detected by antibodies are indicated in bold in (B) and (D).

107 to higher stability of the cleaved hSNAP25, which remains on the membrane, compared to the cleaved
 108 QF2 which becomes cytosolic.

109 Both TEV and BoNT/A are cytosolic proteins, usually made in a host plant or in the *C. botulinum*
 110 bacterium, respectively. For this reason it was important to verify the activity of these proteins when
 111 produced as membrane fusions exposed on the outside of *Drosophila* cells. We found that our extracel-
 112 lular TEV construct was inactive until we mutated the amino-acid Threonine in position 173 to Valine
 113 (TEV^{T173V}) removing a predicted glycosylation site (Fig. S4C-G and supplemental text 7.1.3). Next,
 114 we tested the function of our plasma membrane-targeted BoNT/A using a cell mixing experiment. We
 115 transfected two cell populations: 1. Donor cells with either membrane targeted BoNT/A::GFPnb::CD2
 116 and 2. Receiver cells with receptor and sensors (Fig. 2C). After incubating one day to allow plas-
 117 mid expression, Donor and Receiver cells were rinsed several times to remove traces of transfection
 118 reagents and mixed together. Two days later we could detect hSNAP25 cleavage, confirming that our

119 BoNT/A::GFPnb::CD2 fusion protein was able to pass from the Donor cell to the cytoplasmic com-
120 partment of the Receiver cell to cleave the hSNAP25 based sensor proteins (Fig. 2D). Interestingly we
121 found that TEV^{T173V}::CD2 was not essential for this transfer, perhaps due to TEV independent cleavage
122 and release of BoNT/A::GFPnb from the Donor cell membrane. Critically, just as for the experiments
123 with bacterial BoNT/A::GFPnb (Fig. 2B), we observed a strict requirement for TfR::GFP in Receiver
124 cells.

125 2.3. BAcTrace works as a transsynaptic system in flies

126 Our cell culture results established essential principles for BAcTrace: that *Drosophila* cells can make
127 functional BoNT/A::GFPnb::CD2 which jumps from Donor to Receiver cells, that it can enter the
128 Receiver cell cytoplasm, cleave a hSNAP25 target site, releasing QF2 to drive reporter gene expression.
129 We therefore made transgenic flies to test the system *in vivo*. Donor neuron components were encoded
130 in UAS vectors, driven by Gal4, with Receiver neuron components driven by the LexA system. For
131 transsynaptic experiments, flies containing all BAcTrace components were crossed to flies with Gal4
132 and LexA promoter fusions (Fig. 3A); for some experiments the LexA driver was also placed in the
133 BAcTrace fly.

134 We chose the fly olfactory system for initial testing because of the wealth of genetic reagents and its
135 well-studied connectivity (Fig. 3B). Briefly, *Drosophila* has 50 types of peripheral Olfactory Receptor
136 Neurons (ORNs). ORNs of each type (e.g. red neurons in the antenna of Fig. 3B) express one of 50
137 different olfactory receptor genes, conferring responses to a specific set of odours, and a general co-
138 receptor, Odorant receptor Co-Receptor (Orco). ORNs expressing the same receptor relay information
139 to one of 50 glomeruli in the brain's Antennal Lobe (AL). In each glomerulus the axons of 20-100
140 ORNs make strong connections (e.g. ~1215 synapses per PN in glomerulus DM6) onto the dendrites
141 of 1-8 Projection Neurons (PNs); these in turn make a modest number of reciprocal synapses (e.g. ~40
142 synapses per PN in glomerulus DM6) onto ORNs. PN axons project onto Kenyon Cells (KCs) in
143 the calyx of the Mushroom Bodies (MB, required for associative learning) and to the Lateral Horn
144 (LH, required for innate behaviours) [33]. PNs make on average 7 large boutons in the calyx, each
145 containing 40 pre-synaptic sites which are contacted by 220 small postsynaptic elements from 11 KCs
146 [5, 56], making these large synapses good candidates for initial testing. For our tracing experiments it

147 is important to note that PNs connect to KCs randomly [56, 36, 7]; therefore expressing toxin even in
148 a small number of KCs should result in all PNs labelled.

149 We expressed Donor components in KCs using the MB247-Gal4 driver and Receiver components in
150 PNs using the broad LexA driver VT033006-LexA::P65 (Fig. 3C, see also Fig. S5 for the identity of
151 PNs present in the line). We confirmed that BoNT/A::GFPnb::CD2 can be expressed and trafficked
152 throughout KCs, detecting expression in soma, dendrites and axons (Fig. 3D).

153 We first established the background signal of the system *in vivo* by bringing together all components
154 except the driver used to express toxin in the Donor cells. We found low-frequency, stochastic labelling of
155 PNs with the QUAS-Tomato::HA reporter (Fig. 3E1). Our system can amplify very low levels of the LC
156 protease within Receiver cells, so this signal is likely due to weak, Gal4-independent toxin expression in
157 PNs (BACTrace working in *cis* instead of *trans*). To reduce this background, we added a transcriptional
158 stop cassette in front of BoNT/A::GFPnb::CD2 which can be removed by the B3 DNA recombinase
159 [37]. This modification implements a step filter: only cells that express UAS-B3 above a threshold
160 can activate the BoNT/A::GFPnb::CD2 transgene. Fig. 3E2 shows that the stop cassette reduces
161 background in the absence of Gal4. Furthermore, in the absence of the B3 recombinase transgene
162 (Fig. 3E3) there is no stochastic PN labelling, even in the presence of MB247-Gal4, indicating that
163 the remaining stochastic background in Fig. 3E2 is due to Gal4 independent expression of B3. It is
164 worth mentioning that this Gal4 independent expression might happen during development. Besides
165 the stochastic background we found a much lower, non-stochastic background which is not ameliorated
166 by the stop cassette (Fig. 3E3). We mapped the source of this signal to the small V5 tag present in
167 the sensor (Fig. S6 and supplemental text 7.2.2). Except when indicated, in all further experiments we
168 used a modified sensor without V5.

169 After minimising the background, we performed the first *in vivo* transsynaptic experiment. We found
170 that toxin expression in the MB induced strong labelling of most PNs in the VT033006 line (compare
171 Fig. 3E2 and F1). Just as for S2 cells, we found strong labelling even in the absence of TEV (compare
172 Fig. 3F1 and F2). Although further experiments confirmed a small improvement in efficiency with
173 mutant TEV^{T173V} (Fig. S7 and supplemental text 7.2.3), given that it is not essential for labelling
174 we decided to omit it from the remaining experiments. Critically we found an absolute requirement




Figure 3: **BAcTrace in vivo.** (A) Schematic of the genetic strategy for expressing BAcTrace components. The female fly has all UAS, LexAop and QUAS components while the male has a Gal4 driver defining the Donor cells and a LexA driver defining the Receiver cells. (B) Schematic of the fly olfactory system; adapted from [6]. (C) Reporters showing the expression patterns of MB247-Gal4 (blue) and VT033006-LexA::P65 (green). (D) MB247-Gal4 driving expression of BoNT/A::GFPnb::CD2 in the mushroom bodies. (E) BAcTrace negative controls lacking toxin expression. (E1) No Gal4 driver (E2) Same as E1 (no Gal4) but a transcriptional stop has been placed in front of the toxin. The UAS-B3 transgene encoding the DNA recombinase that can remove the stop cassette is present. (E3) Stop cassette present, same as E2, MB247-Gal4 present and UAS-B3 absent. (F) BAcTrace experiments. (F1) All components present as described in Fig. 1D. (F2) Same as F1 except TEV transgene is absent. (F3) Same as F1 except the Syb::GFP receptor is absent. (C), (E) and (F) are full and (D) partial maximum intensity projections of confocal stacks. Epitopes detected by antibodies are indicated in bold in (C-F). All animals are 3-4 days old. Genotypes for each panel in Table S15. Scale bars 30µm.

175 for the Syb::GFP receptor for *in vivo* transfer of toxin (Fig. 3F3), paralleling the requirement of the
176 hTfR::GFP receptor in tissue culture. Although we observed low level stochastic labelling in the absence
177 of receptor in Receiver PN cells (Fig. 3F3), this was at the same level as when we omitted the driver
178 from Donor cells (Fig. 3E2); this strongly suggests that background labelling again originates from
179 low-level toxin expression in Receiver cells rather than receptor independent transfer from Donor cells.
180 The strict requirement for a synaptic component (i.e. Syb::GFP) for active labelling is very significant
181 since it should select for synaptic rather than non-synaptic cell contacts.

182 Our initial test used the MB247-Gal4 to express toxin in all MB KCs. However the MB contains 3 main
183 types of KCs (i.e. α/β , α'/β' and γ) that can be divided into 7 discrete subtypes by split Gal4 drivers
184 [2]. Although the mushroom body as a whole receives random input from PNs [7], it is not known
185 whether there are input biases onto different KC types. We found that expressing toxin in different KC
186 types labelled all presynaptic PNs, but did so with different efficiencies: $\alpha'/\beta' > \alpha/\beta \approx \gamma$ (Fig. S8
187 and supplemental text 7.2.4). This suggests biases in PN input connectivity to different KC subtypes, an
188 observation that should soon be possible to corroborate with Electron Microscopy (EM) connectomics
189 information [50].

190 2.4. BAcTrace expression in Olfactory Receptor Neurons labels connected PNs

191 Having shown that BAcTrace can label the strong, all-to-all PN->KC synapses, we next examined
192 its labelling specificity using an experimental configuration where only a subset of Receiver cells are
193 connected to toxin-expressing Donor cells. We selected the reciprocal synapses from PNs to ORNs
194 (see Fig. 3B) for two reasons: 1. there are very specific Gal4 driver lines available to drive BAcTrace
195 expression in ORN subtypes [10, 17] and 2. while ORN axons make very strong connections to PN
196 dendrites, EM connectomics data identified a moderate strength reciprocal connection between these
197 two cell types [47]. For example, PNs from the DM6 glomerulus make ~ 40 such reciprocal synapses
198 onto their ORNs (Fig. 4A)[55].

199 Given that we expected the reciprocal synapses from the ORN->PN connection to be relatively weak,
200 we began by expressing toxin in the majority of ORNs using Orco-Gal4 (Fig. 4B). In 2-4 days old
201 animals we detected little labelling above background. However, at nine to ten days after eclosion we
202 found consistent labelling in most glomeruli covered by the VT033006-LexA::P65 line (see Fig. 4B).

203 Quantifying BAcTrace labelling over time may therefore be used to characterise synapses of different
204 strengths.

205 Next we expressed toxin in single ORN types and assessed their ability to label their cognate PNs (Fig.
206 4C and Fig. S11). In most cases strong labelling was detected in animals as young as 2 days old, e.g.
207 Or83c, Or88a, Or92a, Or65a and Or98a while in other cases specific labelling took longer, e.g 10-13
208 days for Or47a. While these differences may be due to cell-type specific differences in the number of
209 ORN->PN reciprocal synapses, they could also be the result of expression level variability of BAcTrace
210 components in the different cell types (i.e. detection system components in PNs or toxin in ORNs).

211 In some cases BAcTrace also labelled PNs targeting glomeruli not innervated by Donor cells (+ in Fig.
212 4C and Fig. S11). This could be artifactual background labelling, as characterised before (Fig. 3E2),
213 or might be triggered by non-synaptic contacts from the ORN axons as they traverse the AL to reach
214 their target glomerulus. However the labelling could also be due to unexpected, synaptic contacts; for
215 instance some ORNs and PNs have small processes in neighbouring glomeruli. Furthermore, VT033006
216 includes some multi-glomerular PNs which when labelled in one glomerulus would show signal in several
217 others. Despite these few instances of unexpected labelling, BAcTrace quickly and robustly labelled
218 PNs when toxin was expressed in their connected ORNs.

219 Viral transsynaptic tools such as rabies have the important caveat of being toxic to neurons. While
220 the only known vertebrate target of BoNT/A, hSNAP25, is not cleaved in flies, we cannot rule out
221 the existence of other targets or cytotoxic effects. To assess these possibilities, we used BAcTrace
222 to label DC3 PNs while expressing the light gated cation channel CsChrimson in Donor, connected
223 Or83c ORNs [25](Fig. 4D). We stimulated the ORNs using light while performing electrophysiological
224 recordings from the Tomato labelled PNs in 14 days old flies (we obtained similar results on 5 days
225 old animals, not shown). If BoNT/A::GFPnb::CD2 was toxic to neurons or detrimental to synaptic
226 transmission then we would expect PNs would fail to respond. We found the opposite to be true,
227 graded light stimulation induced increasing spiking responses in PNs indicating that ORNs are able to
228 release neurotransmitter and stimulate connected PNs. These responses could be partially blocked by
229 the nicotinic acetylcholine receptor blocker mecamylamine, indicating the responses are due to synaptic
230 transmission from ORNs. Furthermore, light responses were absent from Tomato negative control




Figure 4: BACTrace expression in ORNs labels connected PNs. (A) Summary of ORN->PN forward and reciprocal connectivity [55]. Left: aggregated numbers of forward and reciprocal synapses between PNs and ORNs in the DM6 glomerulus. Right: plot showing forward and reciprocal synapses per PN. y scale: sqrt (B) BACTrace expression in Orco ORNs induce time dependent labelling in PNs. (C) BACTrace expression in specific ORNs induces labelling in connected PNs (dotted lines). Occasionally labelling is also present in PNs from neighbouring glomeruli and less frequently non-neighbouring ones. Solid white arrowheads indicate neuronal soma and empty white arrowheads indicate glomerulus not innervated by the ORNs. (D) Whole cell patch clamp recording of a BACTrace labelled PN. Left: Schematic showing experimental set up: BACTrace labelled DC3 PNs (magenta) and Chrimson expressing Donor ORNs (white). Recorded cell is filled and labelled with biocytin-streptavidin (yellow). Middle: Maximum intensity projection of a confocal stack showing the recorded DC3 PN. Right: Representative voltage trace and spikes extracted from three light presentations. First spike row corresponds to shown voltage trace. Top: Recording from the cell shown in middle panel. Middle: same as top but with the addition of the nicotinic acetylcholine receptor blocker mecamylamine (200 μ M). Bottom: Recording from a GFP+ but Tomato- neuron showing minimal response to light. Animal in (D) is 14 days old. Epitopes detected by antibodies are indicated in bold in B, C and D. Genotypes for each panel in Table S15. Scale bars 30 μ m.

231 neurons. Lastly, from a technical point of view, this experiment shows that BAcTrace label is strong
232 enough for guiding cell patching using a regular fluorescent reporter.

233 *2.5. Mapping connections in the Lateral Horn*

234 For the last set of experiments we moved to the Lateral Horn (LH) where connectivity is less well
235 understood and projections are more divergent. In the LH, each olfactory PN type has many post-
236 synaptic Lateral Horn Neuron (LHN) partners with whom it shares fewer synapses than in our previous
237 experiments (Fig. 3B). We expressed Receiver components in PNs using the VT033006-LexA::P65 and
238 toxin in a panel of 8 Donor LHN types (Fig. S12A) [13]. All 8 Donors induced labelling of Receiver
239 PNs (Fig. S12B). Consistent with our expectations of weaker connectivity from individual Receiver
240 cells, labelling was only observed in older animals (16-18d but not 2-3d, not shown).

241 Unlike our previous experiments, there were significant differences in Receiver PN labelling across animals
242 having the same Donor LHNs and even among left/right sides of the same brain (e.g. Fig. S13). To
243 better understand these results we carried out a careful quantification, focussing on 2 LHN types for
244 which EM connectivity data is available: PD2a1/b1 [12] and AV1a1 [23] (Fig. 5A) as well as two
245 types for which more limited information is available: PV5c1 and AV6a1 (Fig. S14A). Fig. 5B shows
246 a schematic of the results presented in Fig. 5C. PD2a1/b1 and AV1a1 target the dorsal and ventral
247 LH respectively, with very little spatial overlap between them (Fig. 5A). Each Donor LHN cell type
248 labelled Receiver PNs targeting different glomeruli; for example, VM3 and DM3 are labelled only in
249 PD2a1/b1 while VM4 and VA1d are only labelled in AV1a1. Labelling differences can also be seen in
250 the LH neuropile where the Receiver signal (Halo) has minimal overlap between the lines (compare LH
251 panels in Fig. 5C). Furthermore, in the LH there is close apposition between toxin and Halo signals
252 supporting the idea that labelling is induced by transsynaptic, retrograde transfer.

253 To quantify these results, we first identified the 15 glomeruli with the highest expression level of Receiver
254 components (Fig. S5C), reasoning that weaker glomeruli would be less efficiently labelled. We then
255 scored glomerular labelling using a simple rating system (strong=10, weak=3, no labelling=0). We
256 mixed samples within a single batch and the annotator was blind to genotype until the end of the process
257 when we used toxin staining to identify LHN Donor cell types for each sample. Stacks are available
258 online for readers to examine. The results are summarised per glomerulus in Fig. 5D. When comparing

259 PD2a1/b1 and AV1a1, 12 out of 15 glomeruli were labelled by at least one of the two Donor cell
260 types; 11 of those 12 were labelled with different strengths, suggesting differences in connectivity. We
261 quantified these differences by computing the average distance with and across LHN cell types between
262 the 15 dimensional annotation vectors for each sample (1 dimension per glomerulus, see methods). As
263 expected, the distance was always lowest for comparisons within an LHN cell-type, indicating similar
264 patterns of labelling. For the across cell-type comparisons, PD2a1/b1 and AV6a1 shared the most
265 similar connectivity, differing from AV1a1 and PV5c1 (which clustered together, Fig. 5E).

266 We next asked: is there enough information within single labelled ALs to identify the Donor cell type
267 of each specimen? We addressed this using principal component analysis (PCA) on the labelling an-
268 notations for all ALs. We found the first principal component efficiently separated individual PD2a1/b1
269 and Av1a1 labelled ALs while the second axis improved separation of PV5c1 and AV6a1(Fig. 5F).
270 The labelling therefore contains enough information at the single specimen level to identify connectivity
271 differences between different LHN types, especially those with more dissimilar connections.

272 Having established that BAcTrace show consistent differences in PN labelling when triggered by differ-
273 ent Donor LHNs, we compared these results with previously published data. In Fig. 5G we summarise
274 BAcTrace (BT), EM [12, 23], electrophysiology (EPhys)[24] and Light Microscopy (LM) overlap (see
275 methods) data for PNs and LHNs. The comparison with PD2a1/b1 EM data is particularly informative
276 as there is unequivocal correspondence between the neurons in the split GAL4 line used in our exper-
277 iments and cells reconstructed by EM. For AV1a1 the correspondence is incomplete as the Gal4 line
278 expresses strongly in 2-3 and more weakly in 6-10 neurons, all of which are likely to share similar mor-
279 phologies. In the EM volume only 6 AV1a1 candidates have been identified and traced to varying levels
280 of completion. Besides neuron correspondence, the comparison to EM data rely on the assumption of
281 invariance in connectivity between animals; so far these neurons have only been traced in one brain and
282 to what extent stereotypy will hold true for LHN-PN connections across animals remains to be tested.

283 We found good correspondence between BAcTrace, EM and LM data. For PD2a1/b1 neurons, 5 out of
284 the 7 PN types that provide more than 10 synapses in the EM volume showed significant (>3) labelling
285 in BAcTrace experiments (see also Fig. 5H). In the case of AV1a1, 7 out of 9 PN types with more
286 than 10 EM synapses induced labelling in BAcTrace experiments. Unexpectedly, toxin expression in




Figure 5: Figure legend on next page.

Figure 5: **BACTrace can reveal connections between PNs and LHNs.** (A) Split Gal4 lines LH989 and LH1983 drive GFP expression in LHN cell types PD2a1/b1 and AV1a1, respectively. (B) Schematic of the Antennal Lobe (AL, left) and Lateral Horn (LH, right) depicting the results shown in (C). (C) Single slices from a representative AL and corresponding LH showing PNs labelled by expression of toxin in PD2a1/b1 and AV1a1. The BACTrace reporter Halo is shown in the AL; Halo, Syb::GFP and Toxin are shown in the LH. CD2 stainings (labelling the toxin) have high background outside the neuropile. Examples of glomeruli differentially labelled between the 2 lines (VA1d, VM3, DM3 and VM4) are indicated. (D) Average labelling scoring per glomerulus for PD2a1/b1 (n=13 ALs), AV1a1 (n=10 ALs), PV5c1(n=18 ALs) and AV6a1 (n=13 ALs). Grey dotted line indicates average scoring of 3 (weak). (E) Heatmap of the Manhattan distance between the labelling scorings for each LHN type. (F) Principal Component Analysis for the vectors describing scoring results. (G) Summary of published data for the 4 LHN cell types. R/S: average expression level for Receptor and Sensor (see Fig. S5). BT: BACTrace results as quantified in (C). EM: Electron Microscopy connectivity data. EPhys: Electrophysiological recordings from LHNs during opto-stimulation of PNs [24]. LM: Light Microscopy overlap of single cell PNs and LHNs [8] and methods. (H) 3D renderings of ALs including BT: glomeruli with signal > 3, EM: glomeruli with more than 10 synapses and BT∩EM: meeting both conditions. Glomeruli colouring in BT and EM same as in (D); in BT∩EM green satisfy BT and EM criteria, blue EM only and green BT only. Epitopes detected by antibodies are indicated in bold in A and C. Genotypes for each panel in Table S15. Scale bars (A) 50µm and (C) 10µm.

287 AV1a1 neurons additionally induced strong labelling in DL3 PNs (whereas EM tracing identified just
288 one AV1a-DL3 synapse). While this might represent a false positive for BACTrace, it is intriguing that
289 there is considerable overlap between AV1a1 and DL3 PNs as measured by light microscopy. Furthermore
290 electrophysiological recordings [24] show a response in AV1a1 induced by DL3 PN activation; this raises
291 the possibility that DL3 PNs may connect to some of the AV1a1 neurons weakly labelled by the L1983
292 line that have not yet been characterised by EM.

293 Lastly, assuming animal-to-animal stereotypy, the variability of labelling strength in our data indicates
294 that BACTrace efficiency is not only a function of synapse number. For instance, in PD2a1/b1 ex-
295 periments DM3 PNs were efficiently labelled by just 11 synapses while 43 synapses induced very poor
296 labelling in VA7I, despite VA7I PN expressing sensor and receptor more strongly than VM2 PNs. Future
297 experiments and community feedback will help identify the different factors affecting labelling efficiency.

298 3. Discussion

299 In this study we present the design and implementation of BACTrace and experiments showing its *in vivo*
300 performance. BACTrace is, to our knowledge, the first modular, fully genetically encoded retrograde
301 labelling system as well as the first application of *C. botulinum* neurotoxin as a circuit tracer. In contrast
302 to anterograde systems which identify 'the next neuron' in a circuit, BACTrace reveals neuronal inputs.
303 This is essential for mapping circuits 'backwards', starting in the motor rather than sensory periphery,
304 and enables studies of neuronal integration throughout the brain. Our implementation of BACTrace in

305 *Drosophila* is therefore highly complementary to the recent *trans*-Tango [54] and TRACT [22] systems
306 for anterograde labelling.

307 Exploiting the detailed connectivity information that exists for the fly's olfactory system [55, 5, 33, 23,
308 18, 12, 63] we explored three important and related questions about BAcTrace: First, does labelling
309 occur only in the retrograde direction? Second, is labelling specific? Third, how many synapses are
310 required? Clear support for the retrograde direction of labelling comes from the PN->LHN experiments;
311 comprehensive tracing of PD2a1/b1 and AV1a1 neurons in a whole brain EM volume failed to identify
312 a single reciprocal LHN->PN synapse (Fig. S14D). This implies that the BAcTrace labelling observed
313 must be retrograde. BAcTrace is specific since we only labelled the correct PNs when toxin was expressed
314 in ORNs. This was confirmed by the match between our PN->LHN results and EM connectivity data.
315 Regarding BAcTrace's sensitivity, in our experiments we could detect labelling in connections ranging
316 from 10 synapses (PN->LHN) to >200 synapses (PN->KC). Does this range encompass functional
317 connections? While there is no single answer for how many synapses constitute a 'functional connection',
318 recent work has found that seemingly low connection strengths, in the region of ~2% of a neuron's total
319 post-synaptic budget, can be functional [12, 16, 38, 48]. In the case of PD2a1/b1 and AV1a1 neurons
320 used in this study, the average number of post-synapses per neuron is 673, implying a 2% threshold value
321 of around 12 synapses (Table S16). While these numbers are tentative, they indicate that BAcTrace
322 should be sensitive enough to detect weak, functional connections. Consistent with this, experiments
323 between neurons of high and medium strength connectivity showed consistent labelling patterns on the
324 left and right sides of the brain and between animals (Fig. 3 and Fig. 4). In contrast, experiments on
325 PN->LHN connections, which rely on fewer synapses, showed higher variability (Fig. 5). While this
326 dichotomy could still result from technical issues, it likely reflects higher biological variability in weak
327 connections. Addressing the origin and significance of variable connectivity throughout the nervous
328 system will require analysis of circuit elements in large numbers of individuals; BAcTrace offers a
329 scalable and affordable approach to characterising inter-individual connectivity.

330 In the last decade viral tracers such as rabies have been the primary source of connectivity data [31]
331 but recently rapid advances in technology have made EM connectomics an increasingly viable approach
332 [27]. Given that EM connectomics may reveal dense connectivity for all the neurons within a brain, one

333 might wonder if it will supplant transsynaptic tracing going forwards. However, transsynaptic labelling
334 has numerous advantages, which mean that these approaches should remain complementary rather than
335 competitive for the foreseeable future. First, EM connectomics is limited to post-mortem specimens,
336 while transsynaptic labelling methods can rapidly reveal connectivity in living animals, enabling neurons
337 to be targeted for recording or manipulation or followed over time; furthermore connection based
338 labelling can enable more precise labelling of neurons than can be achieved with genetic drivers alone.
339 Second, EM connectomics will continue to remain prohibitively expensive and resource intensive for
340 many laboratories and for studies requiring the comparison of multiple specimens. Third, although
341 densely reconstructed connectomics datasets have the great advantage that they can reveal all the
342 connections within a brain region, they are still missing important information e.g. identification of
343 excitatory vs inhibitory synapses, electrical synapses, extra-synaptic communication; in contrast genetic
344 tools can provide a readout for these properties. There are also cases in which the two approaches are
345 synergistic: transsynaptic tools are particularly well suited to unequivocally link neurons identified in
346 EM volumes to those labelled by genetic drivers since they simultaneously reveal neuronal morphology
347 and connectivity; this process will be essential to the functional exploitation of the small number of
348 reference connectomes that will become available over the next few years [50, 3].

349 Finally, the BAcTrace strategy should be applicable to other organisms such as mice and fish, which are
350 still out of reach for whole brain EM imaging. Here the main hurdle for implementing BAcTrace might
351 be the toxicity of the wild type toxin light chain. This can be tackled by using re-targeted light chains
352 or even catalytically inactive light chains fused to non-toxic proteases which would 'piggyback' into the
353 neuron [34]. We would encourage other scientists to improve (see supplemental text 7.3.1) and adapt
354 BAcTrace to their specific needs . Many modifications could be implemented, tested and refined using
355 the tissue culture tools and flies developed in this study.

356 4. Acknowledgments

357 This work was supported by a Dorothy Hodgkin Fellowship from the Royal Society to S.C. (DH120072),
358 ERC Starting (211089) and Consolidator (649111) grants and core support from the MRC (MC-
359 U105188491) to G.S.X.E.J. We are grateful to Bazbek Davletov, Enrico Ferrari and Jason Arsenault
360 for sharing reagents and advice at early stages of the project. We acknowledge the Bloomington Stock
361 Center and the Developmental Studies Hybridoma Bank for fly stocks and antibodies. Finally, we would
362 like to thank Richard Benton and all members of the Jefferis group for many insightful comments on
363 the manuscript.

364 5. References

365 References

- 366 [1] Yoshinori Aso, Kornelia Grübel, Sebastian Busch, Anja B Friedrich, Igor Siwanowicz, and Hiromu
367 Tanimoto. The mushroom body of adult drosophila characterized by gal4 drivers. *J Neurogenet*,
368 23(1-2):156–72, 2009.
- 369 [2] Yoshinori Aso, Daisuke Hattori, Yang Yu, Rebecca M Johnston, Nirmala A Iyer, Teri-T B Ngo,
370 Heather Dionne, L F Abbott, Richard Axel, Hiromu Tanimoto, and Gerald M Rubin. The neuronal
371 architecture of the mushroom body provides a logic for associative learning. *Elife*, 3:e04577, Dec
372 2014.
- 373 [3] Alexander Shakeel Bates, Jasper Janssens, Gregory Sxe Jefferis, and Stein Aerts. Neuronal cell
374 types in the fly: single-cell anatomy meets single-cell genomics. *Curr Opin Neurobiol*, 56:125–134,
375 06 2019.
- 376 [4] A H Brand and N Perrimon. Targeted gene expression as a means of altering cell fates and
377 generating dominant phenotypes. *Development*, 118(2):401–15, Jun 1993.
- 378 [5] Nancy J Butcher, Anja B Friedrich, Zhiyuan Lu, Hiromu Tanimoto, and Ian A Meinertzhagen.
379 Different classes of input and output neurons reveal new features in microglomeruli of the adult
380 drosophila mushroom body calyx. *J Comp Neurol*, 520(10):2185–201, Jul 2012.

- 381 [6] Sebastian Cachero and Gregory S X E Jefferis. *Drosophila* olfaction: the end of stereotypy?
382 *Neuron*, 59(6):843–5, Sep 2008.
- 383 [7] Sophie J C Caron, Vanessa Ruta, L F Abbott, and Richard Axel. Random convergence of olfactory
384 inputs in the *drosophila* mushroom body. *Nature*, 497(7447):113–7, May 2013.
- 385 [8] Ann-Shyn Chiang, Chih-Yung Lin, Chao-Chun Chuang, Hsiu-Ming Chang, Chang-Huain Hsieh,
386 Chang-Wei Yeh, Chi-Tin Shih, Jian-Jheng Wu, Guo-Tzau Wang, Yung-Chang Chen, Cheng-Chi
387 Wu, Guan-Yu Chen, Yu-Tai Ching, Ping-Chang Lee, Chih-Yang Lin, Hui-Hao Lin, Chia-Chou Wu,
388 Hao-Wei Hsu, Yun-Ann Huang, Jing-Yi Chen, Hsin-Jung Chiang, Chun-Fang Lu, Ru-Fen Ni, Chao-
389 Yuan Yeh, and Jenn-Kang Hwang. Three-dimensional reconstruction of brain-wide wiring networks
390 in *drosophila* at single-cell resolution. *Curr Biol*, 21(1):1–11, Jan 2011.
- 391 [9] Marta Costa, James D Manton, Aaron D Ostrovsky, Steffen Prohaska, and Gregory S X E Jef-
392 feris. Nblast: Rapid, sensitive comparison of neuronal structure and construction of neuron family
393 databases. *Neuron*, 91(2):293–311, 07 2016.
- 394 [10] Africa Couto, Mattias Alenius, and Barry J Dickson. Molecular, anatomical, and functional organ-
395 ization of the *drosophila* olfactory system. *Curr Biol*, 15(17):1535–47, Sep 2005.
- 396 [11] Bazbek Davletov, Mark Bajohrs, and Thomas Binz. Beyond botox: advantages and limitations of
397 individual botulinum neurotoxins. *Trends Neurosci*, 28(8):446–52, Aug 2005.
- 398 [12] Michael-John Dolan, Ghislain Belliard-Guérin, Alexander Shakeel Bates, Shahar Frechter, Aurélie
399 Lampin-Saint-Amaux, Yoshinori Aso, Ruairí J V Roberts, Philipp Schlegel, Allan Wong, Adnan
400 Hammad, Davi Bock, Gerald M Rubin, Thomas Preat, Pierre-Yves Plaçais, and Gregory S X E
401 Jefferis. Communication from learned to innate olfactory processing centers is required for memory
402 retrieval in *drosophila*. *Neuron*, 100(3):651–668.e8, Nov 2018.
- 403 [13] Michael-John Dolan, Shahar Frechter, Alexander Shakeel Bates, Chuntao Dan, Paavo Huoviala,
404 Ruairí Jv Roberts, Philipp Schlegel, Serene Dhawan, Remy Tabano, Heather Dionne, Christina
405 Christoforou, Kari Close, Ben Sutcliffe, Bianca Giuliani, Feng Li, Marta Costa, Gudrun Ihrke,
406 Geoffrey Wilson Meissner, Davi D Bock, Yoshinori Aso, Gerald M Rubin, and Gregory Sxe Jefferis.

- 407 Neurogenetic dissection of the drosophila lateral horn reveals major outputs, diverse behavioural
408 functions, and interactions with the mushroom body. *Elife*, 8, May 2019.
- 409 [14] Min Dong, Felix Yeh, William H Tepp, Camin Dean, Eric A Johnson, Roger Janz, and Edwin R
410 Chapman. Sv2 is the protein receptor for botulinum neurotoxin a. *Science*, 312(5773):592–6, Apr
411 2006.
- 412 [15] Christine Dubowy and Amita Sehgal. Circadian rhythms and sleep in drosophila melanogaster.
413 *Genetics*, 205(4):1373–1397, Apr 2017.
- 414 [16] Johannes Felsenberg, Pedro F Jacob, Thomas Walker, Oliver Barnstedt, Amelia J Edmondson-
415 Stait, Markus W Pleijzier, Nils Otto, Philipp Schlegel, Nadiya Sharifi, Emmanuel Perisse, Carlos S
416 Smith, J Scott Lauritzen, Marta Costa, Gregory S X E Jefferis, Davi D Bock, and Scott Waddell.
417 Integration of parallel opposing memories underlies memory extinction. *Cell*, 175(3):709–722.e15,
418 10 2018.
- 419 [17] Elane Fishilevich and Leslie B Vosshall. Genetic and functional subdivision of the *drosophila*
420 antennal lobe. *Curr Biol*, 15(17):1548–53, Sep 2005.
- 421 [18] Shahar Frechter, Alexander Shakeel Bates, Sina Tootonian, Michael-John Dolan, James Manton,
422 Arian Rokkum Jamasb, Johannes Kohl, Davi Bock, and Gregory Jefferis. Functional and anatomical
423 specificity in a higher olfactory centre. *Elife*, 8, May 2019.
- 424 [19] Daniel G Gibson, Lei Young, Ray-Yuan Chuang, J Craig Venter, Clyde A Hutchison, 3rd, and
425 Hamilton O Smith. Enzymatic assembly of dna molecules up to several hundred kilobases. *Nat*
426 *Methods*, 6(5):343–5, May 2009.
- 427 [20] Gagan D Gupta, M G Swetha, Sudha Kumari, Ramya Lakshminarayan, Gautam Dey, and Satyajit
428 Mayor. Analysis of endocytic pathways in drosophila cells reveals a conserved role for gbf1 in
429 internalization via geecs. *PLoS One*, 4(8):e6768, Aug 2009.
- 430 [21] R. Gupta, E. Jung, and S. Brunak. Prediction of n-glycosylation sites in human proteins.
431 <http://www.cbs.dtu.dk/services/NetNGlyc/>, in preparation 2004.

- 432 [22] Ting-Hao Huang, Peter Niesman, Deepshika Arasu, Donghyung Lee, Aubrie L De La Cruz, Antuca
433 Callejas, Elizabeth J Hong, and Carlos Lois. Tracing neuronal circuits in transgenic animals by
434 transneuronal control of transcription (tract). *Elife*, 6, 12 2017.
- 435 [23] Paavo Huoviala, Michael-John Dolan, Fiona M. Love, Shahar Frechter, Ruairí J.V. Roberts, Zane
436 Mitrevica, Philipp Schlegel, Alexander Shakeel Bates, Yoshinori Aso, Tiago Rodrigues, Hannah
437 Cornwall, Marcus Stensmyr, Davi Bock, Gerald M. Rubin, Marta Costa, and Gregory S.X.E. Jefferis.
438 Neural circuit basis of aversive odour processing in drosophila from sensory input to descending
439 output. *bioRxiv*, 2018.
- 440 [24] James M Jeanne, Mehmet Fişek, and Rachel I Wilson. The organization of projections from
441 olfactory glomeruli onto higher-order neurons. *Neuron*, 98(6):1198–1213.e6, Jun 2018.
- 442 [25] Nathan C Klapoetke, Yasunobu Murata, Sung Soo Kim, Stefan R Pulver, Amanda Birdsey-Benson,
443 Yong Ku Cho, Tania K Morimoto, Amy S Chuong, Eric J Carpenter, Zhijian Tian, Jun Wang,
444 Yinlong Xie, Zhixiang Yan, Yong Zhang, Brian Y Chow, Barbara Surek, Michael Melkonian, Vivek
445 Jayaraman, Martha Constantine-Paton, Gane Ka-Shu Wong, and Edward S Boyden. Independent
446 optical excitation of distinct neural populations. *Nat Methods*, 11(3):338–46, Mar 2014.
- 447 [26] Johannes Kohl, Aaron D Ostrovsky, Shahar Frechter, and Gregory S X E Jefferis. A bidirectional
448 circuit switch reroutes pheromone signals in male and female brains. *Cell*, 155(7):1610–23, Dec
449 2013.
- 450 [27] Jörgen Kornfeld and Winfried Denk. Progress and remaining challenges in high-throughput volume
451 electron microscopy. *Curr Opin Neurobiol*, 50:261–267, 06 2018.
- 452 [28] Marta H Kubala, Oleksiy Kovtun, Kirill Alexandrov, and Brett M Collins. Structural and thermo-
453 dynamic analysis of the gfp:gfp-nanobody complex. *Protein Sci*, 19(12):2389–401, Dec 2010.
- 454 [29] D B Lacy, W Tepp, A C Cohen, B R DasGupta, and R C Stevens. Crystal structure of botulinum
455 neurotoxin type a and implications for toxicity. *Nat Struct Biol*, 5(10):898–902, Oct 1998.
- 456 [30] Sen-Lin Lai and Tzumin Lee. Genetic mosaic with dual binary transcriptional systems in drosophila.
457 *Nat Neurosci*, 9(5):703–9, May 2006.

- 458 [31] Liqun Luo, Edward M Callaway, and Karel Svoboda. Genetic dissection of neural circuits: A decade
459 of progress. *Neuron*, 98(2):256–281, Apr 2018.
- 460 [32] D Ma, N Zerangue, Y F Lin, A Collins, M Yu, Y N Jan, and L Y Jan. Role of er export signals in
461 controlling surface potassium channel numbers. *Science*, 291(5502):316–9, Jan 2001.
- 462 [33] Nicolas Y Masse, Glenn C Turner, and Gregory S X E Jefferis. Olfactory information processing in
463 *drosophila*. *Curr Biol*, 19(16):R700–13, Aug 2009.
- 464 [34] Geoffrey Masuyer, John A Chaddock, Keith A Foster, and K Ravi Acharya. Engineered botulinum
465 neurotoxins as new therapeutics. *Annu Rev Pharmacol Toxicol*, 54:27–51, 2014.
- 466 [35] Mauricio Montal. Botulinum neurotoxin: a marvel of protein design. *Annu Rev Biochem*, 79:591–
467 617, 2010.
- 468 [36] Mala Murthy, Ila Fiete, and Gilles Laurent. Testing odor response stereotypy in the *drosophila*
469 mushroom body. *Neuron*, 59(6):1009–23, Sep 2008.
- 470 [37] Aljoscha Nern, Barret D Pfeiffer, Karel Svoboda, and Gerald M Rubin. Multiple new site-specific
471 recombinases for use in manipulating animal genomes. *Proc Natl Acad Sci U S A*, 108(34):14198–
472 203, Aug 2011.
- 473 [38] Tomoko Ohyama, Casey M Schneider-Mizell, Richard D Fetter, Javier Valdes Aleman, Romain
474 Franconville, Marta Rivera-Alba, Brett D Mensh, Kristin M Branson, Julie H Simpson, James W
475 Truman, Albert Cardona, and Marta Zlatic. A multilevel multimodal circuit enhances action
476 selection in *drosophila*. *Nature*, 520(7549):633–9, Apr 2015.
- 477 [39] Aaron Ostrovsky, Sebastian Cachero, and Gregory Jefferis. Clonal analysis of olfaction in *drosophila*:
478 immunochemistry and imaging of fly brains. *Cold Spring Harb Protoc*, 2013(4):342–6, Apr 2013.
- 479 [40] Andrea Pauli, Friederike Althoff, Raquel A Oliveira, Stefan Heidmann, Oren Schuldiner, Christian F
480 Lehner, Barry J Dickson, and Kim Nasmyth. Cell-type-specific tev protease cleavage reveals cohesin
481 functions in *drosophila* neurons. *Dev Cell*, 14(2):239–51, Feb 2008.

- 482 [41] Barret D Pfeiffer, Teri-T B Ngo, Karen L Hibbard, Christine Murphy, Arnim Jenett, James W
483 Truman, and Gerald M Rubin. Refinement of tools for targeted gene expression in drosophila.
484 *Genetics*, 186(2):735–55, Oct 2010.
- 485 [42] Barret D Pfeiffer, James W Truman, and Gerald M Rubin. Using translational enhancers to increase
486 transgene expression in drosophila. *Proc Natl Acad Sci U S A*, 109(17):6626–31, Apr 2012.
- 487 [43] Jason Phan, Alexander Zdanov, Artem G Evdokimov, Joseph E Tropea, Howard K Peters, 3rd,
488 Rachel B Kapust, Mi Li, Alexander Wlodawer, and David S Waugh. Structural basis for the
489 substrate specificity of tobacco etch virus protease. *J Biol Chem*, 277(52):50564–72, Dec 2002.
- 490 [44] Marco Pirazzini, Ornella Rossetto, Roberto Eleopra, and Cesare Montecucco. Botulinum neuro-
491 toxins: Biology, pharmacology, and toxicology. *Pharmacol Rev*, 69(2):200–235, 04 2017.
- 492 [45] Christopher J Potter, Bosiljka Tasic, Emilie V Russler, Liang Liang, and Liqun Luo. The q system:
493 a repressible binary system for transgene expression, lineage tracing, and mosaic analysis. *Cell*,
494 141(3):536–48, Apr 2010.
- 495 [46] Olena Riabinina, David Luginbuhl, Elizabeth Marr, Sha Liu, Mark N Wu, Liqun Luo, and Chris-
496 topher J Potter. Improved and expanded q-system reagents for genetic manipulations. *Nat Meth-*
497 *ods*, 12(3):219–22, 5 p following 222, Mar 2015.
- 498 [47] Jürgen Rybak, Giovanni Talarico, Santiago Ruiz, Christopher Arnold, Rafael Cantera, and Bill S
499 Hansson. Synaptic circuitry of identified neurons in the antennal lobe of drosophila melanogaster.
500 *J Comp Neurol*, 524(9):1920–56, Jun 2016.
- 501 [48] Sercan Sayin, Jean-Francois De Backer, K P Siju, Marina E Wosniack, Laurence P Lewis, Lisa-
502 Marie Frisch, Benedikt Gansen, Philipp Schlegel, Amelia Edmondson-Stait, Nadiya Sharifi, Corey B
503 Fisher, Steven A Calle-Schuler, J Scott Lauritzen, Davi D Bock, Marta Costa, Gregory S X E
504 Jefferis, Julijana Gjorgjieva, and Ilona C Grunwald Kadow. A neural circuit arbitrates between
505 persistence and withdrawal in hungry drosophila. *Neuron*, 104(3):544–558.e6, Nov 2019.
- 506 [49] Johannes Schindelin, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark Longair, To-
507 bias Pietzsch, Stephan Preibisch, Curtis Rueden, Stephan Saalfeld, Benjamin Schmid, Jean-Yves

- 508 Tinevez, Daniel James White, Volker Hartenstein, Kevin Eliceiri, Pavel Tomancak, and Albert
509 Cardona. Fiji: an open-source platform for biological-image analysis. *Nat Methods*, 9(7):676–82,
510 Jun 2012.
- 511 [50] Philipp Schlegel, Marta Costa, and Gregory Sxe Jefferis. Learning from connectomics on the fly.
512 *Curr Opin Insect Sci*, 24:96–105, 12 2017.
- 513 [51] Yasuhiko Soejima, Jae Man Lee, Yudai Nagata, Hiroaki Mon, Kazuhiro Iiyama, Hajime Kitano,
514 Michiya Matsuyama, and Takahiro Kusakabe. Comparison of signal peptides for efficient protein
515 secretion in the baculovirus-silkworm system. *Central European Journal of Biology*, 8(1):1–7, Jan
516 2013.
- 517 [52] Ben Sutcliffe, Julian Ng, Thomas O Auer, Mathias Pasche, Richard Benton, Gregory S X E Jefferis,
518 and Sebastian Cachero. Second-generation drosophila chemical tags: Sensitivity, versatility, and
519 speed. *Genetics*, 205(4):1399–1408, 04 2017.
- 520 [53] Murphy T. The drosophila gateway™ vector collection.
521 <https://emb.carnegiescience.edu/drosophila-gateway-vector-collection>.
- 522 [54] Mustafa Talay, Ethan B Richman, Nathaniel J Snell, Griffin G Hartmann, John D Fisher, Altar
523 Sorkaç, Juan F Santoyo, Cambria Chou-Freed, Nived Nair, Mark Johnson, John R Szymanski,
524 and Gilad Barnea. Transsynaptic mapping of second-order taste neurons in flies by trans-tango.
525 *Neuron*, 96(4):783–795.e4, Nov 2017.
- 526 [55] William F Tobin, Rachel I Wilson, and Wei-Chung Allen Lee. Wiring variations that enable and
527 constrain neural computation in a sensory microcircuit. *Elife*, 6, May 2017.
- 528 [56] Glenn C Turner, Maxim Bazhenov, and Gilles Laurent. Olfactory representations by *drosophila*
529 mushroom body neurons. *J Neurophysiol*, 99(2):734–46, Feb 2008.
- 530 [57] Berrak Ugur, Kuchuan Chen, and Hugo J Bellen. Drosophila tools and assays for the study of
531 human diseases. *Dis Model Mech*, 9(3):235–44, Mar 2016.

- 532 [58] Koen J T Venken, Julie H Simpson, and Hugo J Bellen. Genetic manipulation of genes and cells
533 in the nervous system of the fruit fly. *Neuron*, 72(2):202–30, Oct 2011.
- 534 [59] Katrin Vogt, Yoshinori Aso, Toshihide Hige, Stephan Knappek, Toshiharu Ichinose, Anja B Friedrich,
535 Glenn C Turner, Gerald M Rubin, and Hiromu Tanimoto. Direct neural pathways convey distinct
536 visual information to drosophila mushroom bodies. *Elife*, 5, 04 2016.
- 537 [60] P Washbourne, R Pellizzari, G Baldini, M C Wilson, and C Montecucco. Botulinum neurotoxin
538 types a and e require the snare motif in snap-25 for proteolysis. *FEBS Lett*, 418(1-2):1–5, Nov
539 1997.
- 540 [61] Ryosuke Yagi, Yuta Mabuchi, Makoto Mizunami, and Nobuaki K Tanaka. Convergence of mul-
541 timodal sensory pathways to the mushroom body calyx in drosophila melanogaster. *Sci Rep*,
542 6:29481, 07 2016.
- 543 [62] Daisuke Yamamoto and Masayuki Koganezawa. Genes and circuits of courtship behaviour in
544 drosophila males. *Nat Rev Neurosci*, 14(10):681–92, Oct 2013.
- 545 [63] Zhihao Zheng, J Scott Lauritzen, Eric Perlman, Camenzind G Robinson, Matthew Nichols, Daniel
546 Milkie, Omar Torrens, John Price, Corey B Fisher, Nadiya Sharifi, Steven A Calle-Schuler, Lucia
547 Kmecova, Iqbal J Ali, Bill Karsh, Eric T Trautman, John A Bogovic, Philipp Hanslovsky, Gregory
548 S X E Jefferis, Michael Kazhdan, Khaled Khairy, Stephan Saalfeld, Richard D Fetter, and Davi D
549 Bock. A complete electron microscopy volume of the brain of adult drosophila melanogaster. *Cell*,
550 Jul 2018.

551 Supplemental data

552 6. Material and Methods

553 6.1. Molecular cloning and transgenic flies

554 Backbones of plasmids used in S2 cell experiments were based on the *Drosophila* Gateway vector
555 collection (kind gift from the Murphy lab [53]). Backbones of plasmids used for making transgenic flies
556 were derived from pJFRC19 [41], pJFRC81 [42] and pJFRC161 [37]. Synthesised DNA sequences were
557 codon optimised for *Drosophila* expression and made by GeneArt (Thermo Fisher Scientific, Inc) or IDT
558 (Integrated DNA Technologies, Inc).

559 Plasmids were made using Gibson assembly [19]. All fragments were PCR amplified with overlapping
560 primers yielding scarless products. All fusions were sequenced to control for mutations introduced during
561 the cloning. GenBank accession numbers for all constructs can be found in Tables S10, S11, S12 and
562 S13. Transgenic flies were made by BestGene Inc.

563 Briefly, components for each plasmid were generated as follows:

564 *pAWG-hTfR::Syb*

565 The intracellular portion and transmembrane segment of the hTfR followed by the extracellular segment
566 of *Drosophila* Synaptobrevin were codon optimised and synthesised. The backbone of pAWG was PCR
567 amplified. See Fig. 2A.

568 *pAFW-hSNAP25*

569 Full length hSNAP25 was PCR amplified from a plasmid source (kind gift from Bazbek Davletov).
570 The backbone of pAFW was PCR amplified. The resulting fusion creates an N-terminal FLAG-tagged
571 hSNAP25. See Fig. 2A.


572 *pAFW-QF2::V5::hSNAP25::Syx*

573 Amino acids 1-183 and 660-817 from QF were amplified by PCR and fused to create QF2 similarly to
574 in [46]. Amino acids 141-206 from hSNAP25 were amplified adding a V5 tag to the 5' end primer.
575 Finally, full length *Drosophila* Syntaxin was amplified. All fragments were fused together with a PCR

576 amplified pAFW backbone taking care that the N-terminal flag was in frame with the QF2. See Fig.
577 2A.

578 *pGEX-kg-BoNT/A::GFPnb*


579 BoNT/A protease and translocation domains were PCR amplified from a plasmid source (kind gift
580 from Bazbek Davletov). A *Drosophila* codon optimised anti-GFP nanobody [28] was synthesised and
581 PCR amplified. Both fragments were assembled together with the PCR amplified pGEX-kg backbone
582 for expression in *E. coli*. In this construct there are two thrombin cleavage sites. One separates the
583 GST from the toxin (used to release the toxin from the affinity column during purification) and the
584 second thrombin site separates the toxin protease and translocation domains; this site is cleaved during
585 purification and allows for light chain release after translocation.



586

587 *pJFRC81-BoNT/A::GFPnb::CD2*

588 BoNT/A sequence was codon optimised and synthesised. At the N-terminus a PAT3 signal peptide
589 sequence from *C. elegans* was added for endoplasmic reticulum targeting. C-terminal to the toxin an
590 anti-GFP nanobody was placed (codon optimised, [28]) followed by a full length rat CD2 (excluding
591 the first 20 amino acids encoding its signal peptide) ending with the ER export signal from Kir2.1. In
592 between the toxin light and heavy chains and between the GFPnb and CD2 we introduced TEV and
593 Thrombin cleavage sites, the latter for experiments not discussed in this work.




594

595 *pAWH-BoNT/A-LC*

596 BoNT/A-LC was codon optimised, synthesised and PCR amplified. Note that the codon optimisa-
597 tion was different from that used in pJFRC81-BoNT/A::GFPnb::CD2. The PCR fragment was then

598 assembled with a pAWH backbone PCR amplified. The final product puts the LC in frame with a
599 C-terminal HA tag from the vector.



600

601 *pAWH-TEV^{T173V}::CD2*


602 TEV^{T173V} was PCR amplified in two fragments from a plasmid source (non-condon optimised) with the
603 T173V being introduced in the overlapping segment between both fragments. Full length rat CD2 was
604 amplified by PCR. See Fig. S4C.

605 *QUAS-3xHalo*

606 3xHalo::CAAX-P10 was PCR amplified from a plasmid (Addgene #87646) and assembled with the
607 backbone of QUAS-mtdTomato PCR amplified (excluding the mtdTomato). See [52].

608 *UAS-B3RT-B2-B3RT-BoNT/A*

609 B2 was PCR amplified from pJFRC153-20XUAS-IVS-B2::PEST (Addgene #32134). A tandem of
610 Hsp70b and SV40 3'UTRs was PCR amplified followed by BoNT/A::GFPnb::CD2 amplified from
611 pJFRC81-BoNT/A::GFPnb::CD2. B3 recombination sites were located in front of B2 and in front
612 of the toxin signal peptide. In this way B3 recombination activity removes B2 and the Hsp70-SV40
613 UTRs placing the toxin under control of the UAS driven promoter.



614

615 *UAS-B3RT-BoNT/A*

616 The B2-Hsp70-SV40 coding sequences were removed by crossing a fly containing UAS-B3RT-B2-B3RT-
617 BoNT/A to a fly containing Nos-Gal4 (providing Gal4 in the germ line) and UAS-B3. Progeny from
618 this cross was then PCR screened for loss of the B2 cassette. Isolated flies keep a B3RT site product of
619 the recombination. We found this scar in the DNA to have no noticeable impact on Toxin expression
620 (not shown).

621 *UAS-B3RT-B2-B3RT-HBMB_oNT/A*


622 This construct was made by replacing the PAT3 signal peptide that drives the toxin into the ER by the
623 HoneyBee Melittin signal peptide. HBM signal peptide was shown to be the most efficient peptide of
624 several tested in the baculovirus protein expression system [51].

625 *LexAop2-Syb::GFP-P10*

626 Synaptobrevin was PCR amplified from genomic fly DNA. GFP-P10 was amplified from pJFRC81. The
627 backbone of pJFRC19 was PCR amplified. See Fig. S7B.

628 *LexAop2-QF2::V5::hSNAP25::Syx*

629 QF2::V5::hSNAP25::Syx was PCR amplified from pAFW-QF2::V5::hSNAP25::Syx and assembled with
630 the PCR amplified backbone of pJFRC19.




631

632 *LexAop2-QF2::V5::hSNAP25::HIVNES::Syx*

633 The flag tag present between hSNAP25 and Syntaxin in LexAop2-QF2::V5::hSNAP25::Syx was replaced
634 by site directed mutagenesis with the nuclear export signal from HIV. See Fig. S6A.

635 *LexAop2-QF2::hSNAP25::HIVNES::Syx*

636 The V5 tag present between QF2 and hSNAP25 in LexAop2-QF2::V5::hSNAP25::HIVnes::Syx was
637 replaced by site directed mutagenesis with a GlySer linker.



638

639 *LexAop2-HIVNES::QF2::V5::hSNAP25::Syx*

640 Two rounds of site directed mutagenesis were used on LexAop2-QF2::V5::hSNAP25::Syx to replace the
641 flag tag between hSNAP25 and Syntaxin for a GlySer linker and to then introduce an HIV nuclear export
642 signal in front of QF2. See Fig. S6A.

643 *LexAop2-QF2::V5::hSNAP25::HIVNES::Syx-Hsp70UTR*

644 Hsp70b 3' UTR was PCR amplified from fly genomic DNA and assembled with the plasmid LexAop2-
645 HIVNES::QF2::V5::hSNAP25::Syx amplified with a reverse primer at the end of Syntaxin and a forward
646 primer after the SV40 3'UTR. This strategy replaces the SV40 3'UTR by the Hsp70 3'UTR. See Fig.
647 S6A.

648 *LexAop2-lowUTR-QF2::V5::hSNAP25::HIVNES::Syx-Hsp70UTR*


649 The Syn21 5' UTR from LexAop2-QF2::V5::hSNAP25::HIVNES::Syx-Hsp70UTR was replaced via site
650 directed mutagenesis with the canonical *Drosophila* Kozak sequence CAAA. See Fig. S6A.

651 *LexAop2-QF2-Syntaxin*

652 Site directed mutagenesis was used to remove hSNAP25 from LexAop2-QF2::V5::hSNAP25::HIVNES::Syx.
653 See Fig. S6A.

654 *LexAop2-RSRT-Flp1-RSRT-TEV::CD2-P10*

655 The Flp1 DNA recombinase was PCR amplified and a recombination site for R DNA recombinase
656 (RSRT) added on the 5' end. Hsp70-SV40 was amplified with a second RSRT site on the 3' end.
657 TEV was codon optimised and synthesised. Full length rat CD2 was PCR amplified. P10 was amplified
658 from pJFRC81. The backbone of pJFRC19 was PCR amplified. Gibson assembly was used to generate
659 LexAop2-RSRT-Flp1-RSRT-TEV::CD2-P10.




660

661 *LexAop2-RSRT-TEV::CD2-P10*

662 Flies with this insert were made by crossing LexAop2-RSRT-Flp1-RSRT-TEV::CD2-P10 flies to flies
663 containing UAS-Flp and Nos-Gal4 (providing Gal4 in the Germ line). Progeny from this cross was
664 then PCR screened for lost of the Flp1 cassette. Isolated flies keep an RSRT site product of the
665 recombination. We found this scar in the DNA to have little or no impact on Toxin expression (not
666 shown).

667 *LexAop2-RSRT-Flp1-RSRT-TEV^{T173V}::CD2-P10*

668 The T173V mutation was introduced by site directed mutagenesis on LexAop2-RSRT-Flp1-RSRT-
669 TEV::CD2-P10.




670

671 *LexAop2-RSRT-TEV^{T173V}::CD2-P10*

672 Flies were made by removing the Flp1 cassette from LexAop2-RSRT-Flp1-RSRT-TEV^{T173V}::CD2-P10
673 as in LexAop2-RSRT-TEV::CD2-P10.

674 *LexAop2-RSRT-TEV^{3xmut}::CD2-P10*

675 A triple TEV mutant with all 3 potential glycosylation sites mutated was synthesised. Note that this
676 sequence was codon optimised and synthesised using a different supplier than wild type TEV and
677 therefore codon usage is slightly different. Following PCR amplification TEV was assembled together
678 with the fragment resulting from PCR amplification of LexAop2-RSRT-TEV::CD2-P10 using a forward
679 primer downstream of TEV and a reverse primer upstream of TEV. This strategy replaces TEV with
680 TEV^{3xmut}. Transgenic flies were made and the Flp1 cassette was removed as in LexAop2-RSRT-
681 TEV::CD2-P10.



682

683 *LexAop2-Syb::GFP^{N146I}*

684 The N146I mutation was introduced in LexAop2-Syb::GFP using site directed mutagenesis. See Fig.
685 S7B.

686 *LexAop2-Syb::GFP^{N146I}::TEV*

687 TEV was PCR amplified from LexAop2-RSRT-Flp1-RSRT-TEV::CD2-P10 and assembled with the PCR
688 amplification of LexAop2-Syb::GFP^{N146I} using primers that anneal downstream of GFP^{N146I}. See Fig.
689 S7B.

690 *LexAop2-Syb::GFP^{N146I}::TEV^{T173V}*

691 TEV^{T173V} was amplified from LexAop2-RSRT-Flp1-RSRT-TEV^{T173V}::CD2-P10 and assembled with the
692 PCR amplification of LexAop2-Syb::GFP^{N146I} using primers that anneal downstream of GFP^{N146I}. See
693 Fig. S7B.

694 *pAWG-mCherry::TEVs::V5::CD2*

695 mCherry was PCR amplified from a plasmid source with a TEV cleavage site and a V5 tag on the
696 reverse primer. Full length rat CD2 (excluding the first 20 amino acids encoding its signal peptide) was
697 PCR amplified from a plasmid source incorporating the TEV cleavage site and V5 tag on the forward
698 primer to allow for overlap with mCherry. The pAWG backbone was PCR amplified with overlapping
699 primers in such a way that the mCherry::TEVs::V5::CD2 would be cloned in frame with the GFP from
700 the backbone. See Fig. S7C.

701 *pAWG-mCherry::V5::CD2*

702 The TEV site in pAWG-mCherry::TEVs::V5::CD2 deleted using site directed mutagenesis. See Fig.
703 S7C.

704 6.2. S2 cell transfections

705 S2 cells were acquired from ThermoFisher Scientific (cat no R69007) and cultured according to the
706 manufacturer recommendations. Once the culture was established the cells were transferred from
707 Serum containing Schneider's medium into increasing proportions of serum free Express 5 medium
708 (ThermoFisher Scientific, cat no 10486025).

709 Plasmid DNA for S2 cell transfections was prepared using a MidiPrep DNA purification kit according
710 to the manufacturer instructions (QIAGEN, cat no 12143) .

711 S2 cell transfections were done in 6 well plates, each well containing 2ml of 1×10^6 cells/ml. A total
712 of 2 μ g of plasmid DNA was diluted with culture medium to a volume of 100 μ l and the mixture was
713 vortexed. 3 μ l of FuGENE-HD transfection reagent (Promega, cat no E2311) were added to the diluted
714 DNA, mixed gently and incubated for 10 minutes at room temperature. This mixture was then added
715 drop-wise to the well with cells and the plate was put back into the incubator for 24h. Cells were then

716 rinsed to remove transfection mix. Depending on the experiment either toxin was added as required (as
 717 shown in Fig. 2A) or cells were mixed 1:1 (as shown in Fig. 2B) followed by further 48h incubation
 718 before staining or western blot analysis.

Plasmid	Lane	
	1-5	6-10
pAFW-QF2::V5::hSNAP25::Syx	150	150
QUAS-mtdTomato	250	250
pAFW-hSNAP25	100	100
pAWG-hTfR::Syb	500	-
pJFRC19-Gateway	1000	1500

Table S1: Amounts of plasmid DNA used for experiments presented in Fig. 2B. DNA amounts are in ng.

Plasmid	Lane					
	1,2,5,6R	2D	3,4,5D	3,7R	4,8R	6,7,8D
pJFRC81-BoNT/A::GFPnb::CD2	-	1000	1000	-	-	-
pAFW-hSNAP25	500	-	-	500	500	-
pAWG-hTfR::Syb	500	-	-	500	-	-
pAWH-TEV ^{T173V} ::CD2	-	500	-	500	-	-
pBlueScript	600	-	500	100	1100	-
pMT-Gal4	-	500	500	-	-	-
pAFW-QF2::V5::hSNAP25::Syx	150	-	-	150	150	-
QUAS-mtdTomato	250	-	-	250	250	-
pAWH-BoNT/A-LC	-	-	-	-	-	2000

Table S2: Amounts of plasmid DNA used for experiments presented in Fig. 2D. DNA amounts are in ng. R = Receiver and D = Donor.

719

Plasmid	
pAFW-hSNAP25	500
pAWG-hTfR::Syb	500
pBlueScript	1000

Table S3: Amounts of plasmid DNA used for experiments presented in Fig. S4A. DNA amounts are in ng.

Plasmid	Lane		
	1,4	2,5	3,6
pAFW-QF2::V5::hSNAP25::Syx	150	150	150
QUAS-mtdTomato	250	250	250
pAFW-hSNAP25	100	100	100
pAWG-hTfR::Syb	250	500	1000
pJFRC19-Gateway	1250	1000	500

Table S4: **Amounts of plasmid DNA used for experiments presented in Fig. S4B.** DNA amounts are in ng.

Plasmid	Lane						
	1	2	3	4	5	6	7
pAWG-mCherry::TEVs::V5::CD2	1500	1500	1500	-	-	-	-
pAWG-mCherry::V5::CD2	-	-	-	1500	1500	1500	-
pAWH-TEV ^{T173V} ::CD2	-	500	-	-	500	-	-
pAWH-TEV::CD2	-	-	500	-	-	500	-
pAWH	500	-	-	500	-	-	-

Table S5: **Amounts of plasmid DNA used for experiments presented in Fig. S4G.** DNA amounts are in ng.

720 Plasmids for experiments shown in Fig. 2B are listed in Table S1, Fig. 2D in Table S2, Fig. S4A in
 721 Table S3, Fig. S4B in Table S4 and those from Fig. S4G in Table S5.

722 6.3. *BoNT/A::GFPnb* purification from *E. coli*

723 Toxin was purified from *E. coli* using a low temperature expression protocol to improve toxin folding.

724 *Day 1*

- 725 1. Transform pLysS cells with pGEX-kg-BoNT/A::GFPnb or start a plate (TYE) from a glycerol stock.
- 726 2. Incubate at 37°C overnight.

727 *Low temperature expression and purification of GST fusion proteins*

728 *Day 2*

- 729 1. Pick a colony from a plate into 5ml 2xTY medium + 5µl of both ampicillin 50mg/ml and
 730 chloramphenicol 50 mg/ml and incubate overnight at 37°C.

731 *Day 3*

732 2. Inoculate 25ml of 2xTY medium + 25 μ l of both ampicillin and chloramphenicol with 3ml of the
733 overnight culture in a 50ml Falcon and incubate for 4h at 37 $^{\circ}$ C.

734 3. Dilute into 1l of 2xTY medium + 1ml of both ampicillin and chloramphenicol in a 2l flask and grow
735 for 1.5-2h at 37 $^{\circ}$ C. Stop the incubation when the OD at 600nm reaches 0.6.

736 4. Add 1ml of IPTG 100mM to induce BoNT/A::GFPnb expression and **incubate overnight at 20 $^{\circ}$ C.**

737 *Day 4*

738 5. Pellet bacteria using a centrifuge at maximum speed for 20' and discard the supernatant.

739 6. From here on work in ice. Suspend the pellet using 10ml of Lysis buffer. Transfer to a 50ml Falcon
740 tube and rinse the bottle with an extra volume of 10ml. Prepare a 50X stock of Complete protease
741 inhibitor cocktail, Roche (cat no. 4693132001) and add 600 μ l.

742 7. Freeze the Falcon tube in liquid nitrogen for 10' (can pause here by storing frozen pellet in -80 $^{\circ}$ C
743 freezer) and then thaw it in a water bath at room temperature.

744 8. Add 12 μ l of 1M MgCl₂ and a tip of deoxyribonuclease I from bovine pancreas. Rotate at room
745 temperature for 10'.

746 9. Add Triton X-100 for a final concentration of 2% and incubate for 20' at 4 $^{\circ}$ C.

747 10. Equilibrate a GST column (Pierce, cat no 16107) to 4 $^{\circ}$ C. Remove bottom tab by twisting and place
748 in a 15ml Falcon tube.

749 11. Centrifuge column at 700g for 2min to remove storage buffer.

750 12. Equilibrate with two resin bed volumes (2-3ml) of equilibration/wash buffer from Pierce kit. Allow
751 buffer to enter resin bed by gently inverting several times.

752 13. Centrifuge column at 700g for 2min to remove buffer.

753 14. Pellet the cell lysate using a centrifuge at 4 $^{\circ}$ C for 30min at 7000g (we use reusable round bottomed
754 PPCO 50ml tubes from Nalgene which fit a JA25.50 rotor). Save 20 μ l of the supernatant for later
755 SDS-PAGE analysis.

756 15. Add as much lysate to the column as fits (roughly 5-6ml) and allow it to enter the resin bed by
757 gently inverting several times. Incubate at 4 $^{\circ}$ C with rotation for 30min-1h.

- 758 16. Centrifuge the column at 700g for 2min, collect flow through and save an aliquot for SDS-PAGE
759 analysis.
- 760 17. Repeat previous two steps until all the sample has been loaded on the column. About 3 times.
- 761 18. Wash resin with 2ml of equilibration/wash buffer from Pierce kit. Centrifuge at 700g for 2min
762 and collect flow through for analysis. Repeat at least 2 times. Monitor the absorbance at 280nm and
763 perform additional washes until the absorbance approaches baseline.
- 764 19. Keep some beads for SDS-PAGE analysis.
- 765 20. Wash resin with 2ml of buffer A twice to remove DTT and triton X-100.
- 766 21. Cap the bottom of the column with the white cap provided with the kit and then add 1.5ml of
767 buffer A and 25 units of thrombin and incubate for 30min at 37°C in an orbital shaker at 100rpm.
- 768 22. Remove cap, put column in a 15ml falcon tube and spin at 700xg for 2min. Save the flow-through
769 containing the toxin.
- 770 23. Repeat the thrombin treatment twice and save the flow-throughs.
- 771 24. Remove the GST-tags by rinsing the column with 2ml of elution buffer.
- 772 25. Centrifuge at 700xg for 2min.
- 773 26. Repeat the GST-tag elution twice more.
- 774 27. Regenerate the columns as recommended by the manufacturer.
- 775 28. Toxin can then be concentrated and buffer can be exchanged using Amicon spin columns. For
776 BoNT/A::GFPnb toxin, buffer was exchanged for PBS, toxin was filtered and aliquoted and stored at
777 -80°C.

Lysis Buffer 500ml	
20mM HEPES	10ml of 1M
500mM NaCl	50ml of 5M
1mM EDTA	1ml of 0.5M
1mM DTT	0.5ml of 1M
Buffer A 500ml	
20mM HEPES	10ml of 1M
100mM NaCl	10ml of 5M
2xTY 1000ml	
Tryptone	16g
Yeast extract	10g
NaCl	5g
Take volume to 1l, adjust pH to 7.4 if needed and autoclave	
TYE plates	
Agar	15g
NaCl	8g
Bacto Tryptone	10g
Yeast extract	5g
Take volume to 1l and autoclave. Pour on plates.	

Table S6: **Solutions used during toxin purification.**

778 *6.4. Western blot analysis*

779 Cells for western blot analysis were resuspended in culture medium, pelleted, rinsed in PBS and pelleted
780 again. Pellets were resuspended in 1x sample buffer (ThermoFisher Scientific, cat no NP0007) with
781 a reducing agent (ThermoFisher Scientific, cat no NP0004) and heat denatured. Samples were then
782 loaded in 12% bis-tris gels (ThermoFisher Scientific, cat no NP0342BOX) and run using MOPS buffer
783 (ThermoFisher Scientific, cat no NP0001). Gels were transferred to PVDF membranes (Millipore Inc,
784 cat no IPVH00010) and developed using the antibodies shown in Table S7 and ECL reagents (GE
785 Healthcare Ltd, cat no RPN2232) following the manufacturer recommendations. HRP conjugated
786 secondary antibodies were purchased from Cell Signalling Technology, Inc.

Species	Target	Concentration	Supplier	Cat no
Rabbit	FLAG	1:1000	Cell Signalling	2368
Mouse	rat CD2	1:2000	GeneTex	GTX75123
Chicken	GFP	1:5000	Abcam	ab13970
Rat	HA	1:4000	Roche	11 867 423 001

Table S7: **Antibodies used in western blot experiments.**

787 *6.5. Brain staining*

788 For a full description of brain stainings see [39].

789 Briefly:

- 790 1. Dissect brains in 1xPB and keep them on ice.
- 791 2. Fix for 30' in 4% paraformaldehyde in 1xPB.
- 792 3. Rinse 3-4 times with PBT, 10min each, in a rotating wheel.
- 793 4. Block between 1h and over night in block solution (5% normal goat serum in PBT).
- 794 5. Incubate in primary antibodies diluted in block solution for 2-3days at 4°C on a rotating wheel.
- 795 6. Wash 3-4 times with PBT, 2-3h each, in a rotating wheel at room temperature.
- 796 7. Incubate in secondary antibodies diluted in block solution for 2-3days at 4°C on a rotating wheel.
- 797 8. Wash 3-4 times with PBT, 2-3h each, in a rotating wheel at room temperature.
- 798 9. Equilibrate over night in Vectashield (Vector Laboratories, cat no H-1000).
- 799 10. Mount on slides and image.

800 In cases where chemical labelling and immunostaining were required, the former was done first as
801 described in [52] and at the end of the protocol, instead of adding Vectashield, brains were put through
802 the immunostaining procedure as described above. Solutions are listed in Table S8 and antibodies in
803 Table S9.

PB - Phosphate buffer	
NaH ₂ PO ₄ · H ₂ O	4.363 g
Na ₂ HPO ₄ (anhydrous)	9.705 g
Take volume to 1l	
PBT (PBS + 0.3% Triton X-100)	
NaCl	7.325g
Na ₂ HPO ₄ (anhydrous)	2.36g
NaH ₂ PO ₄ · 2 H ₂ O	1.315g
Triton X-100	3g
Take volume to 1l	

Table S8: **Solutions used for brain immunostainings.**

Species	Target	Concentration	Supplier	Cat no
Mouse	Bruchpilot	1:40	DSHB	AB_2314866
Mouse	rat CD2	1:200	GeneTex	GTX75123
Rabbit	Tomato/RFP/mCherry	1:1000	antibodies-online	ABIN129578
Chicken	V5	1:800	Bethyl	A190-118A
Chicken	GFP	1:1000	Abcam	ab13970

Table S9: **Antibodies used for brain immunostainings.**

804 *6.6. Image acquisition*

805 Confocal stacks of fly brains were imaged at 768×768 pixels every $1 \mu\text{m}$ (voxel size of $0.46 \times 0.46 \times$
806 $1 \mu\text{m}$; 0.6 zoom factor) using an EC Plan-Neofluar $40\times/1.30$ Oil DIC M27 objective and 16-bit color
807 depth. For LHN glomeruli scoring higher magnification images were taken at 1024×1024 pixels every
808 $0.5 \mu\text{m}$ (voxel size of $0.19 \times 0.19 \times 0.5 \mu\text{m}$; 1-1.1 zoom factor). All images were acquired using Zeiss
809 LSM710 and Zeiss LSM880 confocal microscopes.

810 *6.7. Fluorescence quantification*

811 To quantify the expression levels of Syb::GFP and QF2::V5::hSNAP25::Syx driven by the VT033006-
812 LexA::P65 driver (S5) we co-stained brains for the neuropile marker Bruchpilot and GFP and Bruchpilot
813 and V5 respectively. We then acquired high magnification confocal stacks of the stained ALs. Next we
814 split the Zeiss LSM files into NRRD files using FIJI [49] followed by segmentation of each glomerulus by
815 drawing a region of interest in the centre of the glomerulus (the plane which captured most of its area).
816 Both glomerulus identification and segmentation were done using the nc82 channel. Segmentations
817 were saved as ROI files. GFP and V5 mean intensities were obtained using FIJI and were normalised to
818 the mean intensity of the nc82 channel for each glomerulus. This normalisation is intended to counter
819 the drop in intensity due to light scatter when imaging deeper into the tissue.

820 *6.8. Drosophila stocks*

821 Fly stocks were maintained at 25°C on Iberian food. The driver lines used in this study are summarised
822 in Table S14, LexA responsive transgenes in Table S13, Gal4 ones in Table S12 and QUAS ones in
823 Table S11. All brain images are from female flies.

824 6.9. PN->LHN BAcTrace labelling quantification

825 We took high magnification confocal stacks of antennal lobes and used the nc82 channel to identify and
826 annotate glomeruli using regions of interest in FIJI. We assigned a value of 0 (absent), 3 (present but
827 weak) and 10 (strong) to annotated glomeruli by examining the intensity of the QUAS-Halo reporter
828 channel. Once all antennal lobes were annotated we used the toxin labelling (CD2) channel to assign
829 each specimen to the correct LHN cell type.

830 6.10. Light microscopy PN-LHN overlap score

831 In order to quantify the overlap between neuronal skeletons for PNs and LHNs, derived from both
832 light-level and EM data, we employed the 'overlap score' from [18]:

$$f(i_s, j_k) = \sum_{k=1}^n e^{-\frac{d^2}{2\delta^2}}$$

833 Skeletons were resampled so that we considered 'points' in the neuron at 1 μm intervals and an 'overlap
834 score' calculated as the sum of $f(i_s, j_k)$ over all points s of i . Here, i is the axonal portion of a neuron,
835 j is the dendritic portion of a putative target, δ is the distance between two points at which a synapse
836 might occur (e.g. 1 μm), and d is the euclidean distance between points s and k . The sum was taken
837 of the scores between each point in i and each point in j .

838 Overlap scores were calculated between light-level reconstructions from stochastic labelling experiments
839 [13, 8], that have been previously been registered from hundreds of brains to a common template, cat-
840 egorised and identified [9, 18]. We also made use of a complete set of uniglomerular PNs, reconstructed
841 from a single EM dataset comprising a whole fly brain (Bates & Schlegel, in preparation).

842 6.11. Electrophysiology

843 Electrophysiological recordings were carried out as described in [18] with minor modifications. Briefly,
844 one day after eclosion flies were CO₂ anesthetized, females of the correct genotype were selected,
845 transferred to all trans-retinal fly food and kept in the dark. Five days later, flies were cold anaesthetised,
846 placed in the recording chamber and dissected under dim light for recording as described in [26]. Data
847 acquisition was performed as previously described with the only difference that a pco.edge 4.2 CMOS

848 camera was used. For CsChrimson excitation of ORNs, a short (0.5 sec) pulse of light (550nm) was
849 applied via a Cairn OptoLED controller.

850 7. Supplemental text

851 7.1. *BACTrace* is active in *Drosophila* cells

852 7.1.1. Designing a *BoNT/A::GFPnb* receptor for S2 cells

853 While *Syb::GFP* was designed to target the toxin to neuronal neurotransmitter vesicles in flies, we
854 reasoned it might not work in non-neuronal S2 cells. To overcome this limitation, in tissue culture
855 experiments we replaced *Syb::GFP* with a chimera between GFP and the human transferrin receptor
856 (*hTfR::GFP*). A similar construct has previously been shown to traffic to a low pH compartment in S2
857 cells [20]. We also tested chimeras between GFP and the *Drosophila* protein eater (*FBgn0243514*) and
858 the scavenger receptor *Cl* (*FBgn0014033*) and found that, similarly to *GFP::hTfR*, both were able to
859 support *Flag::hSNAP25* cleavage (not shown).

860 7.1.2. Sensitivity of S2 cells to *BoNT/A::GFPnb*

861 All concentrations of toxin tested in Fig. 2B. showed nearly complete *hSNAP25* cleavage. This
862 motivated us to repeated the experiment using lower toxin concentrations. We found that as little as
863 0.1 to 0.3pM of toxin caused 50% *hSNAP25* cleavage after 2 days of incubation (Fig. S4A). We also
864 tried different amounts of plasmid encoding the toxin receptor and found that increases beyond 250 ug
865 did not improve *Flag::hSNAP25* cleavage, even though it resulted in higher amounts of *GFP::hTfR* as
866 detected by WB (Fig. S4B).

867 7.1.3. Optimising TEV for extracellular activity

868 To release the membrane tethered *BoNT/A::GFPnb* from the post-synapse we chose to use the Tobacco
869 Etch Protease (TEV) fused to the transmembrane protein CD2. In plants, viral TEV is cytosolic while in
870 our system TEV is targeted to the cell surface. We reasoned that post-translational modifications in the
871 secretory pathway (e.g. glycosylation) might impact TEV's activity. We tested this by co-expressing
872 *TEV::CD2* and *mCherry::TEVsite::CD2::GFP* ("TEV sensor" in Fig. S4C) in S2 cells. Fluorescence

873 microscopy and western blot analysis indicated limited cleavage of the extracellular mCherry protein by
874 wild type TEV (red solid arrowheads in Fig. S4D and G). The lack of extracellular TEV activity lead
875 us to analyse TEV's secondary structure where we found three predicted N-Glycosylation sites: N23,
876 N52 and N171 (Fig. S4E and blue residues in F). We mutagenised the three sites individually (N23Q,
877 T54V and T173V) and re-tested for Sensor cleavage activity. After mutating threonine 173 to valine
878 (T173V) there was little mCherry signal left in the plasma membrane and the Sensor band was absent
879 from the western blot (red open arrowheads in Fig. S4D and G). Consistently with this result, N171
880 has been shown to interact with the substrate during the catalysis while the other two sites are further
881 away from the active site [43].

882 *7.2. BAcTrace works as a transsynaptic system in flies*

883 *7.2.1. Using LexA to drive BAcTrace components in Receiver neurons*

884 We reasoned that driving the detection system with LexA instead of tying it to pan-neuronal expression
885 would allow more flexibility into the system; for example, Receiver neurons might have too many inputs
886 and by using restricted LexA drivers these inputs could be immediately broken down by anatomical (e.g.
887 using a LexA line specific for olfactory projection neurons), physiological (e.g LexA neurotransmitter
888 specific) or other criteria for which LexA drivers are available.

889 *7.2.2. V5 tag is non-specifically cleaved inducing sensor background*

890 To identify the source of and minimise the non-stochastic, toxin-independent background we made a
891 series of flies carrying modified sensors (Fig. S6A). We hypothesised that one possible reason for the
892 background could be the sensor not inserting properly in the membrane and therefore being free to
893 migrate to the nucleus and activate the QUAS-effector in the absence of cleavage. To counter this we
894 inserted the Nuclear Export Signal of the AIDS virus (HIV-NES) between hSNAP25 and Syntaxin. In
895 this position this peptide will keep the protein out of the nucleus until toxin cleavage separates QF2
896 from it. Nevertheless we found this strategy failed to remove the background (Fig. S6A1 and B1).
897 The HIV-NES is functional as inserting it N-terminal to QF2 removes any detectable background (Fig.
898 S6A2 and B2).

899 We also designed two more sensors with weaker UTRs and found that expression level is not the main
900 problem as both showed non-stochastic background. Nevertheless, we did confirm that the UTRs have
901 an impact in expression levels as detected by the V5 tag (Fig. S6A3,4 and B3,4).

902 Lastly we made a construct lacking hSNAP25 to address the possibility of non-specific cleavage, maybe
903 triggered by unusual interactions between hSNAP25 and *Drosophila* Syntaxin. To our surprise we found
904 a much weaker V5 signal (compare Fig. S6B5 and B1) and a strong QUAS-Tomato signal, much
905 stronger than the non-stochastic background.

906 Based on these set of results we reasoned that the source of the background is non-specific cleavage
907 N-terminal to QF2 but not in the hSNAP25. The considerably weaker V5 signal in Fig. S6B5 suggests
908 the V5 tag is being either cleaved and thus becomes non-immunogenic or cleavage in Syntaxin creates
909 a more unstable cytosolic QF2::V5. Nevertheless, the fact that the HIV-NES in Fig. S6B1 is not active
910 seems to support the cleavage of V5 as the source of background. We confirmed this hypothesis by
911 creating a sensor like Fig. S6A1 but with the V5 replaced by a gly-ser linker. We found this sensor to
912 be completely silent in the absence of toxin.

913 7.2.3. TEV mutants modestly increase labelling efficiency

914 To further explore the impact of TEV in our system we repeated the experiments shown in Fig. 3F
915 using the T173V mutant and a triple mutant in all three glycosylation sites. To allow the detection
916 of increases in labelling efficiency for these experiments we used the split Gal4 line MB005C instead of
917 MB247. MB005C drives toxin expression in a smaller subset of Kenyon cells (350 α' β' neurons) than
918 MB247-Gal4 (c. 1650 neurons of most types [1]). Using one or two copies of TEV::CD2 we could not
919 detect an increase in labelling when compared to the no TEV control, implying that wild type TEV
920 does not make toxin transfer more efficient (Fig. S7A1-3). Next we tested TEV^{T173V} (Fig. S4D-G)
921 and a triple TEV mutant that abolishes all three sites (Fig. S4E). We found these mutants induce a
922 modest increase in labelling efficiency of PNs. From this experiment it is not clear if the effect is due
923 to cleavage between the toxin and CD2 (i.e. improving toxin release) or in the belt region (i.e. allowing
924 LC detachment after translocation). The contribution of each site could be addressed by using toxins
925 with only one TEV site.

926 Because extracellular TEV::CD2 is made inefficiently, as judged by antibody staining of CD2 (not

927 shown), we reasoned that targeting it with Synaptobrevin instead of CD2 would increase its synaptic
928 concentration and activity. Additionally, we wanted to mitigate the TEV independent toxin transfer
929 mediated by Syb::GFP receptor. To this end we made a new receptor using a mutant GFP, GFP^{N146I},
930 that has 10 time less affinity for the GFPnb than wild type GFP [28] (Fig. S7B1 and 2). We found
931 this new receptor (Syb::GFP^{N146I}) to be equally efficient as the one with wild type GFP (compare
932 Fig. S7C1 and C2). We used this lower affinity receptor to target TEV. GFP staining indicated
933 Syb::GFP^{N146I}::TEV accumulates less than Syb::GFP^{N146I} possibly due to a de-stabilising effect of TEV
934 (compare Fig. S7C2 and C3). Interestingly, this was partially alleviated by the T173V mutation in
935 Syb::GFP^{N146I}::TEV^{T173V}(compare Fig. S7C3 and C4). Furthermore, while Syb::GFP^{N146I}::TEV barely
936 induced labelling of PNs the converse was true for Syb::GFP^{N146I}::TEV^{T173V}. This result mimics what
937 we found in tissue culture, i.e. that the T173V mutant has increased activity, either due to increased
938 stability or proteolytic activity.

939 7.2.4. Subsets of Kenyon cells induce differential labelling of PNs

940 MB247-Gal4 is expressed in most KCs [1] and induces labelling on most Receiver PNs. In order to
941 confirm this results and test BAcTrace at this synapse further, we used a panel of split Gal4 lines that
942 label different subsets of KCs [2]. PN to KC connections in the adult fly are random [36] therefore
943 we expected that the smaller the subset of KCs expressing BAcTrace the weaker the label would be,
944 eventually resulting in fewer labelled PNs. In order to expedite the genetics in this experiment we
945 made a new QUAS-3xHalo7 [52] reporter on the X chromosome. While this reporter recapitulates the
946 previously used QUAS-mtdTomato it is considerably less sensitive (compare Fig. S9A and B).

947 A negative control missing a hemidriver failed to induce PN labelling (Fig. S8A). When both hemidrivers
948 were present, expression in all subsets of KCs produced labelling in most Receiver PNs (Fig. S8B). Toxin
949 expression in discrete KC subsets also induced labelling in Receiver PNs (Fig. S8C-E). Furthermore,
950 qualitatively we didn't see differences in the identity of the labelled PNs between the driver lines.
951 However, the strength of labelling in PNs did not simply correlate with the number of KCs expressing
952 toxin. For instance MB418B which only labels 140 α'/β' m neurons induces labelling as strongly as
953 MB010B which labels 1940 neurons of most subtypes. Labelling strength was $\alpha'/\beta' > \alpha/\beta \approx \gamma$.
954 This observation might be explained by a higher connectivity of α'/β' m KC than the other subtypes,

955 more efficient toxin transfer through these synapses or stronger BAcTrace expression. The influence of
956 expression strength can be seen in lines MB370B and MB463B which drive expression in the same cells
957 at different levels and show different labelling efficiencies (Fig. S8C).

958 Another unexpected result was the relatively weak labelling induced by γ d KCs. These neurons have
959 dendrites in the ventral accessory calyx where they receive inputs from visual projection neurons and
960 have been reported to not receive input from olfactory PNs [61, 59]. The labelling observed is unlikely
961 to be of larval origin as most labelled PNs are not present in the larva. Several possible scenarios might
962 contribute to the observed labelling: during metamorphosis there might be exploratory contacts from
963 olfactory PNs which are later pruned, the use of non-localising toxin might have led to extra-synaptic
964 contacts or alternatively there might exist real contacts between PNs and γ d KCs which went undetected
965 in the two aforementioned studies. In support of this later possibility γ d KCs have process in the main
966 calyx which are stained by the dendritic marker DenMark (see Fig. 2B in [59]). Higher magnification
967 images of brains mounted dorsal side up also showed toxin puncta in the the calyx of the MB, in close
968 apposition to labeled PNs (Fig. S8F). Using temporal control of toxin expression and localising the
969 toxin to dendrites might shed more light on these results.

970 Lastly, we did experiments to assess the impact of components' dosage in labelling efficiency. We used
971 MB005B to drive toxin in 350 KCs. We found that having a second copy of the toxin or the receptor
972 has little to no impact (Fig. S10A and B). On the other hand, having a second copy of the LexA driver
973 induced a noticeable increase in labelling (Fig. S10C). While background staining increased as well,
974 this experiments were done with the V5 containing sensor; we anticipate background would be mostly
975 absent when using the newer sensor. A note of caution is due here, in this and other experiments using
976 two copies of VT033006-LexA::P65 we noted unusual PN morphologies, e.g. axons terminating early
977 and with simpler arborisations. This anomalies could be due to high expression levels of BAcTrace
978 components, a toxic effect of LexA::P65 or the homozygous state of the VT033006-LexA::P65 insertion
979 locus (JK22).

980 7.3. Discussion

981 7.3.1. System Optimisation

982 Based on our results there are several areas where optimisation might increase the sensitivity and
983 flexibility of the system:

984 **Receptor-Ligand:** Fine-tuning this interaction could increase the efficiency of the transfer. For in-
985 stance multimerising the GFP on the Syb::GFP would make more ligand available while multimerising
986 the GFPnb in the toxin would allow each toxin to bind more than one receptor; if the limiting step is
987 the force the receptor exerts to pull the toxin across the cleft then binding 2 or 3 receptors instead of 1
988 might make this process more efficient. In addition GFP could be mutated to make it non-fluorescent
989 or the receptor ligand pair could be replaced altogether.

990 **Sensor:** Our experiments used a full length *Drosophila* Syntaxin as carrier for the QF2::hSNAP25.
991 Syntaxin and SNAP25 are part of the SNARE complex in neurons. In the sensor, these helices are
992 in close proximity potentially pushing them into forming a complex, with or without Synaptobrevin,
993 the third component of the SNARE complex, which could affect the availability of hSNAP25 for toxin
994 cleavage. Once the cleavage takes place, the interaction between the helices could also affect the release
995 of the QF2 which retains 48 amino acids from hSNAP25 on its C terminus (see Fig. 1.A). To explore
996 and potentially mitigate the negative impact of full length Syntaxin, deletions of the sensor should be
997 tested. In addition, we found the Syntaxin sensor to be lethal when expressed very broadly and at high
998 level within the nervous system (e.g. when driven with Syb-LexA::P65). We attribute this toxicity to
999 the overexpression of the Syntaxin portion of the sensor as a similar sensor based in Synaptobrevin did
1000 not show lethality, although it was considerably less sensitive (not shown).

1001 **Genetics:** Transsynaptic systems are by design extremely sensitive and will produce false positives when
1002 used with leaky Gal4 lines or when Gal4 protein persist in the adult after developmental expression. For
1003 this reason all genetically encoded tracing tools will benefit from better genetic means by which to
1004 express tracers. In this study we took a recombinase based approach to activate the toxin transgene
1005 and decrease background. While this is sufficient for the very clean Gal4s in combination with the
1006 very restricted LexA line used here, it will not be enough for many other applications. Approaches
1007 that conditionally refine expression in time by means of temperature sensitive components (e.g. the

1008 temperature sensitive Gal4 repressor Gal80) or fine-tuning the stability of the components will help
1009 tackle this issue.

1010 One important limitation of BAcTrace is that the LexA and Gal4 lines cannot overlap. If they do,
1011 very strong activation takes place in the overlapping cells whereby the toxin gets internalised becoming
1012 unavailable to induce transsynaptic labelling. In future systems the same recombinase that activates
1013 the toxin transgene could be used to remove the DNA encoding the receptor allowing for overlapping
1014 Gal4-LexA expression. This might need to be complemented by a mechanism to trigger the degradation
1015 of receptor made before the DNA recombination.

1016 In addition, new implementations of the system might shy away from using Gal4 and LexA as direct
1017 drivers but they could activate recombinases that in turn switch on component transgenes. In this way
1018 these transgenes could be driven by pan-neuronal promoters making expression levels less variable and
1019 resulting in more comparable results between cell types.

1020 7.4. Supplemental figures

```

1   mpfvnkqfny kdpvngvdia yikipnagqm qpvkafkihn kiwviperdt ftnpeegdlN
61  pppeakqvpv sydstylst dnekdnylkg vtklferiys tdlgrmlts ivrgipfwgg
121 stidtelkvi dtncinviqp dgsyrseeln lviigpsadi iqfecksfgh evlnltrngy
181 gstqyirfsp dftfgfeesl evdtnpllg gkfatdpavt lahelihagh rlygiainpN
241 rvfkvntnay yemsglevsf eelrtfgghd akfidslqen efrlyyyknf kdiastlnka
301 ksivgttasl qymknvfkek yllsedtsGk fsvdklkfdk lykmlteiyt ednfvkffkv
361 lnrktylnfd kavfkinivp kvnytiydgf nlrntnlaan fngqnteinn mnftklknft
421 glfeyyklLC vrgiitsktk sldkgynkaL ndlCikvnmw dlffspsedn ftndlnkgee
481 itsdtnieaa eenisldliq qyyltfnfdn epenisienl ssdiigqlel mpnierfpng
541 kkyeldkytm fhylraqefe hgksrialtn svneallnps rvytffssdy vkkvnkatea
601 amflgwveql vydftdetse vstdkiadi tiiipyigpa lnignmlykd dfgalifsg
661 avillefipe iaipvlgtfa lvsyiankvL tvqtidnals krnekwdevy kyivtnwlak
721 vntqidlirk kmkealenqa eatkaiinyq ynqyteeekN ninfniddls sklnesinka
781 mininkflnq csvsylvmsm ipygvkrled fdaslkdall kyiydnrgtl igqvdrldkdk
841 vnntlstdip fqlskyvdnq rllstfteyi kniintsiln lryesnhlid lsryaskini
901 gskvnfdpid knqiqlfnle sskievilkN aivynsmyen fstsfwirip kyfnsislNn
961 eytiincmen nsgkwvslny geiiwtlqdt qeikqrvvfk ysqminisy inrwifvtit
1021 nrlnnskiy ingrlidqkp isnlgnihas nnimfkldgc rdthryiwik yfnlfdkeln
1081 ekeikdlydn qsnsilkdf wgdylqydkp yymlnlydpn kyvdvnnvgi rgymylkgpr
1141 gsvmttniyl nsslyrgtkf iikkyasgnk dnivrndrv yinvvknke yrlatnasqa
1201 gvekilsale ipdvgnlsqv vvmkskddqg irnkckmnlq dnngndigfi gfhlydniak
1261 lvasnwynrq ierasrtfgc swefipvddg wgessl

```

Figure S1: **Amino acid sequence of BoNT/A1 from Clostridium botulinum (AFN57627.1)**. The protease domain is indicated in red, belt in yellow, translocation domain in green and receptor binding domain in blue, same as in Fig. 1A. Cys 430 and 454 which form a disulphide bond to hold the light and heavy chains together are indicated in capital.




Figure S2: **BoNT/A1 mechanism of action in vertebrates**. Adapted from [11].

```
1 MPPSTLLLL AALLPFALPA SDWKTGEVMT PFvnkqfnyk dpvngvdiay ikipnagqmq
61 pvkafkihnk iwviperdtf tnpeegdlnp ppeakqvpvs yydstylstd nekdnlykgv
121 tklferiyst dlgrmltsi vrgipfwggs tidtelkvid tncinviqpd gsyraseelnl
181 viigpsadii qfecksfghe vlnltnrgyg stqyirfspd ftfgfesle vdtnpllgag
241 kfatdpavtl ahelihaghr lygiaainpr vfkvntnayy emsglevsfe elrtfgghda
301 kfidslqene frlyyykfk diastlnkak sivgttaslq ymknvfkeyy llsedtsgkf
361 svdklkfdkl ykmlteiyte dnfvkffkvl nrktylnfdk avfkinivpk vnytiydgfn
421 lrntnlaanf ngqnteinm nftklknftg lfefykllCv rgiitskts ldkgynkaks
481 gsenlyfqgs glvprgsqal ndlCikvnnw dlffspsedn ftndlnkgee itsdtnieaa
541 eenisldliq qyyltfnfdn epenisienl ssdiigqlel mpnierfpng kkyeldkytm
601 fhylraqefe hgksrialtn svneallnps rvytffssdy vkkvnkatea amflgwveql
661 vydfdtetse vsttdkiadi tiipyigpa lnignmlykd dfvgalifsg avillefipe
721 iaipvlgtfa lvsyiankvl tvqtidnals krnekwdevy kyivtnwlak vntqidlirk
781 kmkealenqa eatkaiinyq ynqyteeekn ninfniddls sklnesinka mininkflnq
841 csvsylvmsm ipygvkrled fdaslkdall kyiynrgtl igqvdrldk vnntlstdip
901 fqlskyvdnq rllstfteyi knirsgmqvq lvesggalvq pggslrlsca asgfpvnrys
961 mrwyrqapgk erewvagsm agdrssyeds vkgrftisrd darntvylqm nslkpedtav
1021 yycnvnvgfe ywgqgtqvtv ssksggypyd vpdyagsenl yfqqgslvpr gsgsdcrdsg
1081 tvwgalghgi nlnipnfqmt ddidevrwer gstlvaefkr kmkpflksa feilangdlk
1141 iknltrddsg tynvtvystn gtrildkald lrilemvskp miywecsnat ltcevlegtd
1201 velklyqgke hlrslrqktm syqwtlnrap fkckavnrvs qesemevnc pekglplyli
1261 vgvsaggl11 vffgalfifc ickrkkrrr rkgeeleika srmstvergp kphstqasap
1321 asqnpvasqa ppppghhlt pghrplppsh rnrehqpkkp pppsgtqvhq qkgpplprpr
1381 vqpkppcgsg dvslppnen ansfcyenev al
```

Figure S3: **Amino acid sequence of BAcTrace BoNT/A::GFPnb::CD2**. Colours as in Fig. S1 except the signal peptide for ER targeting which is indicated in purple and capital, the anti-GFP nanobody in blue, rat CD2 in orange and the C-terminal Kir2.1 ER export signal to improve trafficking to the plasma membrane in grey [32]. TEV sites for toxin release are underlined.




Figure S5: **Expression strength of VT033006-LexA::P65.** **(A)** V5 tag immunostaining of QF2::V5::hSNAP25::Syx in VK000018. **(B)** GFP immunostaining of Syb::GFP in VK000037. **(C)** Quantification of fluorescence per glomerulus from A and B. Each glomerulus measured in 6 ALs from 3 brains. Leftmost panel in (A) and (B) are maximum intensity projections while all other panels are single slices from confocal microscopy stacks. Epitopes detected by antibodies are indicated in bold in A and B. Scale bars 30 μ m.




Figure S6: **V5 tag induces non-specific activation of the toxin sensor.** (A) Schematic of the sensors used in (B). (B) Background expression of the sensors from (A) in the absence of toxin. Maximum intensity projections of registered confocal stacks from age matched animals; images taken using the same microscope settings. Epitopes detected by antibodies are indicated in bold in B. Scale bars = 30 μ m.




Figure S7: **TEV^{T173V} modestly increases BAcTrace efficiency.** (A) BAcTrace labelling of PN from sparse KC Donors driven by MB005C. (A1) TEV negative control, (A2) one copy and (A3) two copies of wild type TEV show no difference in labelling efficiency. All (A4), one copy of TEV^{T173V}, (A5), one copy of TEV^{3xmut} and (A6), two copies of TEV^{3xmut}, show a modest increase in labelling when compared to the no TEV control (A1). (B) Schematic of constructs used in (C) for minimising TEV independent labelling. (C) (C1) Control with the regular Syb::GFP receptor. (C2) Lower affinity Syb::GFP^{N146I} receptor still supports efficient transsynaptic labelling. (C3) Addition of wild type TEV to the Syb::GFP^{N146I} in (C2) decreases expression and transsynaptic labelling. (C4) Introducing T173V mutation in TEV from (C3) increases expression strength and labelling efficiency. Maximum intensity projections of registered confocal stacks from age matched animals; images taken using the same microscope settings. Epitopes detected by antibodies are indicated in bold in (A) and (C). Scale bars 30µm.




Figure S8: **BAcTrace expression in subsets of KCs induces labelling in PN.** (A) Negative control missing a split Gal4 hemidriver. Donor KCs: (B) all, (C) α'/β' , (D) γ and (E) α/β . (F) Higher magnification view of the MB calyx and LH of a brain with Donor MB607B neurons (same as in D). The brain was mounted dorsal side up to provide better image quality of the MB calyx and LH. Within each lobe subtypes are: γ lobe: main (m) and dorsal (d), α'/β' lobe: anterior-posterior (ap) and middle (m) and α/β : posterior (p), core (c) and surface (s). Maximum intensity projections of registered confocal stacks from age matched animals; (A), (B), (C) and (D) taken using the same microscope settings. Epitopes detected by antibodies are indicated in bold in each panel. Number of KCs per subtype from [2]. Scale bars 30 μ m.




Figure S9: **Sensitivity of BAcTrace QUAS-reporters.** BAcTrace labelling of VA1d PNs using Or88a ORNs as Donors. **(A)** Labelling using QUAS-mtdTomato #26(94E7) from [45]. **(B)** Labelling using QUAS-3xHalo (this work). Maximum intensity projections of registered confocal stacks from age matched animals; images taken using the same microscope settings. Epitopes detected by antibodies are indicated in bold in each panel. Scale bars 30 μ m.




Figure S10: **Effect of manipulating BAcTrace components dosage.** In all experiments we used MB005B (Fig. S8) to drive toxin in ~350 Donor α'/β' KCs. **(A)** Compared to a single copy, two copies of Toxin induce a modest increase in labelling. **(B)** A second copy of receptor induces no increase in labelling. **(C)** A second copy of the LexA driver induces an increase in labelling strength. Note that the sensor used in these experiments has a V5 tag which is the likely source of most background in the absence of toxin. Maximum intensity projections of registered confocal stacks from age matched animals; images taken using the same microscope settings. Epitopes detected by antibodies are indicated in bold in each panel. Scale bars 30 μ m.




Figure S11: **BAcTrace expression in ORNs labels connected PNs.** BAcTrace expression in specific ORNs induces labelling in connected PNs (dotted lines). Occasionally labelling is also induced in PNs from neighbouring glomeruli and less frequently non-neighbouring ones. The age of shown animals were: DM3 10-13 days old, DL3 and VM5v 2-4 days old. Top panel is a maximum intensity projections of registered confocal stacks. 5 next panels are single slices from the same specimen. Epitopes detected by antibodies are indicated in bold in each panel. Scale bars 30µm.




Figure S12: **BACTrace expression in LHNs induce labelling in PNs.** (A) Expression of split Gal4 LHN lines tested. Anti-GFP immunostaining against UAS-csChrimson::mVenus in attP18. Cell types in each line are indicated on the top left and the name of the line on the bottom right. Adapted from [13] (B) For each line animals of two ages were dissected. Several LHs were imaged, registered to a template and averaged to produce the different panels. Bottom two panels on the right are a negative control made from line LH196 with one hemidriver missing. Epitopes detected by antibodies are indicated in bold in each panel. Scale bars (A) = 30 μ m and (B) = 10 μ m.




Figure S13: **LHN-PN connectivity for 2 LHN types in 4 different specimens.** BAcTrace labelled PNs from Donor cells: **(A)** PD2a1/b1 neurons (LH989) and **(B)** AV1a1 neurons (LH1983). Images are maximum intensity projections of confocal stacks, affine registered to a template for the AL region. The surface outside the neuropile region was masked out to avoid obscuring the glomeruli. Epitopes detected by antibodies are indicated in bold in each panel. Scale bars = 10 μ m.




Figure S14: **BACTrace can reveal connections between PNs and LHNs.** (A) Split Gal4 lines LH173 and LH1139 drive GFP expression in cell types PV5c1 and AV6a1, respectively. (B) Single slices from a representative antennal lobe and corresponding LH showing PNs labelled by expression of toxin in PV5c1 and AV6a1. The BACTrace reporter Halo is shown in the AL; Halo, Syb::GFP receptor and Toxin are shown in the LH. CD2 stainings (labelling the toxin) have high background outside the neuropile. (C) 3D renderings summarising BACTrace results for PV5c1 and AV6a1. (D) Plot of the number of forward and reciprocal synapses between PNs for the 15 glomeruli analysed in 5 and PD2a1/b1 and AV1a1 as assessed by EM. The number next to the glomerular identity of the PN is its EM identification number. Epitopes detected by antibodies are indicated in bold in (A) and (B). Scale bars (A) 50µm and (B) 10µm.

Name	Source	Plasmid acc.
pAWG-hTfR::Syb	This study	MN658769
pAFW-hSNAP25	This study	MN658770
pAFW-QF2::V5::hSNAP25::Syx	This study	MN658771
pGEX-kg-BoNT/A::GFPnb	This study	MN658772
pJFRC81-BoNT/A::GFPnb::CD2	This study	MN658773
pAWH-BoNT/A-LC	This study	MN658774
pAWH-TEV ^{T173V} ::CD2	This study	MN658775
pAWG-mCherry::TEVs::V5::CD2	This study	MN658793
pAWG-mCherry::V5::CD2	This study	MN658794
pAWH-TEV::CD2	This study	MN658795
pAWH	[53]	-

Table S10: **Plasmids used in S2 cell experiments.**

Insertion site	Transgenes	Source	Plasmid stock number
Cytological band 94E7	QUAS-mtdTomato	Bloomington stock 30005	-
attp3	QUAS-3xHalo	This study	MN658776

Table S11: **QUAS transgenes used in this study.**

Insertion site	Transgenes	Source	Plasmid stock number
attP18 su(Hw)attP8	10XUAS-mCD8::RFP LexAop2-mCD8::GFP(su(Hw)attP8)	Bloomington stock 32229	-
VK00031	3XUAS-B3R::PEST	This study	Addgene 32138
attp2	20XUAS-B3R.PEST	Bloomington stock 55785	-
VK00005	UAS-B3RT-B2-B3RT-BoNT/A	This study	MN658777
	UAS-B3RT-BoNT/A	This study	MN658777 (reduced)
	UAS-B3RT-B2-B3RT-HBMBoNT/A	This study	MN658778
VK00027	UAS-B3RT-B2-B3RT-BoNT/A	This study	MN658777
attP18	20XUAS-csChrimson::mVenus	Bloomington stock 55134	-
attP40	20XUAS-csChrimson::mVenus	Bloomington stock 55135	-

Table S12: **UAS transgenes used in this study.**

Insertion site	Transgenes	Source	Plasmid stock number
VK00037	LexAop2-Syb::GFP-P10	This study	MN658779
Su(Hw)attp5	LexAop2-Syb::GFP-P10	This study	MN658779
attp40	LexAop2-QF2::V5::hSNAP25::Syx	This study	MN658780
VK00018	LexAop2-QF2::hSNAP25::HIVNES::Syx	This study	MN658781
	LexAop2-QF2::V5::hSNAP25::Syx	This study	MN658780
	LexAop2-QF2::V5::hSNAP25::HIVNES::Syx	This study	MN658782
	LexAop2-HIVNES::QF2::V5::hSNAP25::Syx	This study	MN658783
	LexAop2-QF2::V5::hSNAP25::HIVNES::Syx-Hsp70UTR	This study	MN658784
	LexAop2-lowUTR-QF2::V5::hSNAP25::HIVNES::Syx-Hsp70UTR	This study	MN658785
	LexAop2-QF2::V5::Syntaxin	This study	MN658786
Su(Hw)attp2	LexAop2-RSRT-Flp1-RSRT-TEV::CD2-P10	This study	MN658787
	LexAop2-RSRT-TEV::CD2-P10	This study	MN658787 (reduced)
	LexAop2-RSRT-Flp1-RSRT-TEV ^{T173V} ::CD2-P10	This study	MN658788
	LexAop2-RSRT-TEV ^{T173V} ::CD2-P10	This study	MN658788 (reduced)
	LexAop2-RSRT-Flp1-RSRT-TEV ^{3xmut} ::CD2-P10	This study	MN658789
	LexAop2-RSRT-TEV ^{3xmut} ::CD2-P10	This study	MN658789 (reduced)
VK00033	LexAop2-RSRT-TEV::CD2-P10	This study	MN658787 (reduced)
VK00002	LexAop2-Syb::GFP ^{N146I}	This study	MN658790
	LexAop2-Syb::GFP ^{N146I} ::TEV	This study	MN658791
	LexAop2-Syb::GFP ^{N146I} ::TEV ^{T173V}	This study	MN658792

Table S13: **LexAop transgenes and LexA drivers used in this study.** lowUTR indicates the construct does not have Syn21 or L21 5'UTRs for enhancing protein expression.

Insertion site	Line Name	Genotype	Cell types	Source
JK22C		VT033006-LexA::p65	Multiple PN types	Yoshinori Aso
NA		MB247-Gal4	All KCs	Bloomington stock 50742
NA		Orco-Gal4	Multiple ORN types	Bloomington stock 26818
NA		Or83c-Gal4	Or83 ORNs	Bloomington stock 23132
NA		Or88a-Gal4	Or88 ORNs	Bloomington stock 23294
NA		Or92a-Gal4	Or92 ORNs	Bloomington stock 23139
NA		Or47a-Gal4	Or47 ORNs	Bloomington stock 9982
NA		Or65a-Gal4	Or65 ORNs	Bloomington stock 9994
NA		Or98a-Gal4	Or98 ORNs	Bloomington stock 23141
attp40 attp2	LH1479	w ; 84F07-p65ADZp ; 65C07-ZpGAL4DBD	AV4b3 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp40 attp2	LH1139	w ; 93A02-p65ADZp ; 44G08-ZpGAL4DBD	AV6a1 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp2	37G11	w ; 37G11-GAL4	PD2a1/b1 LHNs	Bloomington stock 49539
attp40 attp2	LH196	w ; 79C09-p65ADZp ; 31B01-ZpGAL4DBD	PD3a1 LHNs	Jefferis lab
attp40 attp2	LH542	w ; 42D01-p65ADZp ; 86A05-ZpGAL4DBD	PV4a1:5 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp40 attp2	LH1554	w ; 91F03-p65ADZp ; 71D08-ZpGAL4DBD	PV5b1 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp40 attp2	LH173	w ; 16C09-p65ADZp ; 28A10-ZpGAL4DBD	PV5c1 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp40 attp2	LH719	w ; 34C08-p65ADZp ; 17B08-ZpGAL4DBD	PV5c1 LHNs	Jefferis lab
attp40 attp2	LH2033	w ; VT043152-p65ADZp ; VT027015-ZpGAL4DBD	PV12a1 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp40 attp2	LH989	w ; 29G05-p65ADZp ; 37G11-ZpGAL4DBD	PD2a1/b1 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp40 attp2	LH1983	w ; 76E07-p65ADZp ; VT008671-ZpGAL4DBD	AV1a1 LHNs	http://splitgal4.janelia.org/cgi-bin/splitgal4.cgi
attp40 attp2	MB010B	w ; R13F02-p65ADZp ; R52H09-ZpGAL4DBD	KC: γ main, α'/β' ap, α'/β' m, α/β c, α/β p and α/β s	Bloomington stock 68293
attp40 attp2	MB005B	w ; R13F02-p65ADZp ; R34A03-ZpGAL4DBD	KC: α'/β' ap and α'/β' m	Bloomington stock 68306
attp40 attp2	MB370B	w ; R13F02-p65ADZp ; R41C07-ZpGAL4DBD	KC: α'/β' ap and α'/β' m	Bloomington stock 68319
attp40 attp2	MB463B	w ; R35B12-p65ADZp ; R34A03-ZpGAL4DBD	KC: α'/β' ap and α'/β' m	Bloomington stock 68370
attp40 attp2	MB418B	w ; R26E07-p65ADZp ; R30F02-ZpGAL4DBD	KC: α'/β' m	Bloomington stock 68322
attp40 attp2	MB131B	w ; R13F02-p65ADZp ; R89B01-ZpGAL4DBD	KC: γ main and γ d	Bloomington stock 68165
attp40 attp2	MB419B	w ; R26E07-p65ADZp ; R39A11-ZpGAL4DBD	KC: γ d	Bloomington stock 68323
attp40 attp2	MB607B	w ; R19B03-p65ADZp ; R39A11-ZpGAL4DBD	KC: γ d	Bloomington stock 68256
attp40 attp2	MB008B	w ; R13F02-p65ADZp ; R44E04-ZpGAL4DBD	KC: α/β c, α/β p and α/β s	Bloomington stock 6825C91
attp40 attp2	MB185B	w ; R52H09-p65ADZp ; R18F09-ZpGAL4DBD	KC: α/β s	Bloomington stock 68267

Insertion site	Line Name	Genotype	Cell types	Source
attp40 attp2	MB594B	w ; R13F02-p65ADZp ; R58F02-ZpGAL4DBD	KC: α/β c	Bloomington stock 68255

Table S14: Driver lines used in this study.

Figure	Genotype
3C	w 10XUAS-mCD8::RFP(attP18) LexAop2-mCD8::GFP(su(Hw)attP8) ; VT033006-LexA::p65 / + ; MB247-Gal4 <i>QUAS-mtdTomato::HA</i> / +
3D	w ; ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / MB247-Gal4 <i>QUAS-mtdTomato</i>
3E1	w ; LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attp40) / VT033006-LexA::p65(JK22C) ; UAS-B3RT-BoNT/A(VK00005) / <i>QUAS-mtdTomato</i>
3E2	w ; LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attp40) / VT033006-LexA::p65(JK22C) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attp2) / <i>QUAS-mtdTomato</i>
3E3	w ; LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attp40) / VT033006-LexA::p65(JK22C) ; UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / MB247-Gal4 <i>QUAS-mtdTomato</i>
3F1	w ; LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attp40) / VT033006-LexA::p65(JK22C) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attp2) / MB247-Gal4 <i>QUAS-mtdTomato</i>
3F2	w ; LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attp40) / VT033006-LexA::p65(JK22C) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / MB247-Gal4 <i>QUAS-mtdTomato</i>
3F3	w ; LexAop2-QF2::V5::hSNAP25::Syx(attp40) / VT033006-LexA::p65(JK22C) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attp2) / MB247-Gal4 <i>QUAS-mtdTomato</i>
4B	w ; Orco-GAL4 VT033006-LexA::p65(JK22C) / LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) ; <i>QUAS-mtdTomato::HA</i> / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)
4C DC3	w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) / CyO ; <i>QUAS-mtdTomato::HA</i> Or83c-GAL4 / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)
4C VA1d	w ; VT033006-LexA::p65(JK22C) Or88a-Gal4 / LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) ; <i>QUAS-mtdTomato::HA</i> / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)
4C VA2	w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) / CyO ; <i>QUAS-mtdTomato::HA</i> Or92a-GAL4 / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)
4D	<i>QUAS-3xHalo(attp3)</i> w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) / UAS-CsChrimson::mVenus(attp40) ; <i>QUAS-mtdTomato::HA</i> Or83c-GAL4 / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)
5A PD2a1	w 10XUAS-mCD8::RFP(attP18) LexAop2-mCD8::GFP(su(Hw)attP8) / + ; 29G05-p65ADZp(attp40) / + ; 37G11-ZpGdbd(attp2) / +

Figure	Genotype
5A AV1a1	w UAS-csChrimson::mVenus(attP18) / w ; 76E07-p65ADZp(attp40) / + ; VT008671-ZpGAL4DBD(attp2) / +
5C PD2a1/b1 S13A	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) / 29G05-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 37G11-ZpGdbd(attp2)
5C AV1a1 S13B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2--SNAP25-HIVNES-Syx(VK00018) / 76E07-AD(atpp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / VT008671-DBD(attp2)
S5A	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; MKRS / TM6
S5B	w ; LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attp40) / VT033006-LexA::p65(JK22C) ; UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / MB247-Gal4 QUAS-mtdTomato
S7A1	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S7A2	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attp2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S7A3	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; LexAop2-RSRT-TEV::CD2-P10(VK00033) 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attp2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S7A4	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV ^{T173V} ::CD2-P10(Su(Hw)attp2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S7A5	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV ^{3xmut} ::CD2-P10(Su(Hw)attp2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S7A6	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attp2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S7C1	w ; LexAop2-Syb::GFP-P10(Su(Hw)attp5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / VT033006-LexA::p65(JK22C) ; UAS-B3RT-B2-B3RT-HBMBoNT/A(VK00005) 3XUAS-B3R::PEST(VK00031) / MB247-Gal4 QUAS-mtdTomato
S7C2	w ; LexAop2-Syb::GFP ^{N146I} (VK00002) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) / VT033006-LexA::p65(JK22C) ; UAS-B3RT-B2-B3RT-HBMBoNT/A(VK00005) 3XUAS-B3R::PEST(VK00031) / MB247-Gal4 QUAS-mtdTomato
S7C3	w ; LexAop2-Syb::GFP ^{N146I} ::TEV(VK00002) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) / VT033006-LexA::p65(JK22C) ; UAS-B3RT-B2-B3RT-HBMBoNT/A(VK00005) 3XUAS-B3R::PEST(VK00031) / MB247-Gal4 QUAS-mtdTomato

Figure	Genotype
S7C4	w ; LexAop2-Syb::GFP ^{NI46I} ::TEV ^{T173V} -P10(VK00002) LexAop2-QF2::hSNAP25::HIVNES::Syx(VK00018) / VT033006-LexA::p65(JK22C) ; UAS-B3RT-B2-B3RT-HBMB ^{BoNT/A} (VK00005) 3XUAS-B3R::PEST(VK00031) / MB247-Gal4 QUAS-mtdTomato
S8A	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 52H09-ZpGdbd(attP2)
S8B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 13F02-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 52H09-ZpGdbd(attP2)
S8C MB005B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 13F02-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 34A03-ZpGdbd(attP2)
S8C MB370B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 13F02-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 41C07-ZpGdbd(attP2)
S8C MB463B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 35B12-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 34A03-ZpGdbd(attP2)
S8C MB418B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 26E07-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 30F02-ZpGdbd(attP2)
S8D MB131B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 13F02-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 89B01-ZpGdbd(attP2)
S8D MB419B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 26E07-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 39A11-ZpGdbd(attP2)
S8D MB607B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 19B03-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 39A11-ZpGdbd(attP2)
S8E MB008B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 13F02-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 44E04-ZpGdbd(attP2)
S8E MB185B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 52H09-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 18F09-ZpGdbd(attP2)
S8E MB594B	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 13F02-p65ADZp(attP40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / 58F02-ZpGdbd(attP2)
S9A	w ; VT033006-LexA::p65(JK22C) Or88a-Gal4 / LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00005) UAS-B3RT-B2-B3RT- ^{BoNT/A} (VK00027) / QUAS-mtdTomato::HA

Figure	Genotype
S9B	w QUAS-3xHalo(attP3) / y ; VT033006-LexA::p65(JK22C) Or88a-Gal4 / LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / TM6
S10A 1x Toxin	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attP5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S10A 2x Toxin	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attP5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S10B No Receptor	w ; LexAop2-QF2::V5::hSNAP25::Syx / VT033006-LexA::p65(JK22C) ; LexAop2-RSRT-TEV::CD2-P10(VK00033) 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attP2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S10B 1x Syb::GFP	w ; LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attP40) / VT033006-LexA::p65(JK22C) ; LexAop2-RSRT-TEV::CD2-P10(VK00033) 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attP2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S10B 2x Syb::GFP	w ; LexAop2-Syb::GFP-P10(Su(Hw)attP5) LexAop2-Syb::GFP-P10(VK00037) LexAop2-QF2::V5::hSNAP25::Syx(attP40) / VT033006-LexA::p65(JK22C) ; LexAop2-RSRT-TEV::CD2-P10(VK00033) 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV::CD2-P10(Su(Hw)attP2) / R13F02-p65ADZp(VK00027) R34A03-ZpGAL4DBD(attP2) QUAS-mtdTomato::HA
S10C No Toxin 1xVT033006-LexA	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attP5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; MB247-Gal4 QUAS-mtdTomato::HA/TM2
S10C No Toxin 2xVT033006-LexA	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attP5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / VT033006-LexA::p65(JK22C) ; MB247-Gal4 QUAS-mtdTomato::HA/ TM2
S10C 1xVT033006-LexA	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attP5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / CyO ; pJFRC158-3XUAS-B3R::PEST(VK00031) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV ^{T173V} ::CD2-P10(Su(Hw)attP2) / MB247-Gal4 QUAS-mtdTomato
S10C 2xVT033006-LexA	w ; VT033006-LexA::p65(JK22C) LexAop2-Syb::GFP-P10(Su(Hw)attP5) LexAop2-QF2::V5::hSNAP25::Syx(VK00018) / VT033006-LexA::p65(JK22C) ; pJFRC158-3XUAS-B3R::PEST(VK00031) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) LexAop2-RSRT-TEV ^{T173V} ::CD2-P10(Su(Hw)attP2) / MB247-Gal4 QUAS-mtdTomato
S11 DM3	QUAS-3xHalo(attP3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / CyO ; QUAS-mtdTomato::HA Or47a-GAL4 / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)
S11 DL3	QUAS-3xHalo(attP3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / CyO ; Or65a-Gal4 QUAS-mtdTomato::HA / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)
S11 VM5v	QUAS-3xHalo(attP3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / CyO ; QUAS-mtdTomato::HA Or98a-Gal4 / 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027)

Figure	Genotype
S12 B LH1479	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 84F07-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 65C07-ZpGdbd(attp2)
S12 B LH1139	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 93A02-Gal4AD(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 44G08-Gal4DBD(attp2)
S12 B 37G11	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / + ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 37G11-Gal4(attp2)
S12 B LH196	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 79C09-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 31B01-ZpGdbd(attp2)
S12 B LH542	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 42D01-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 86A05-ZpGdbd(attp2)
S12 B LH1554	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 91F03-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 71D08-ZpGdbd(attp2)
S12 B LH173	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 16C09-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 28A10-ZpGdbd(attp2)
S12 B LH719	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 34C08-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 17B08-ZpGdbd(attp2)
S12 B LH2033	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / VT043152-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / VT027015-ZpGdbd(attp2)
S12 B Negative control	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 79C09-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / +
S6B1	w ; VT033006-LexA::p65(JK22C) / LexAop2-QF2-minSNAP25-HIVNES-Syntaxin(VK00018) ; MB247-Gal4 QUAS-mtdTomato::HA / +
S6B2	w ; VT033006-LexA::p65(JK22C) / LexAop2-HIVNES-QF2-minSNAP25-Syntaxin(VK00018) ; MB247-Gal4 QUAS-mtdTomato::HA / +
S6B3	w ; VT033006-LexA::p65(JK22C) / LexAop2-QF2mSN25SyxHsp70UTR(VK00018) ; MB247-Gal4 QUAS-mtdTomato / +
S6B4	w ; VT033006-LexA::p65(JK22C) / LexAop2-lowUTRQF2mSN25SyxHsp70UTR(VK00018) ; MB247-Gal4 QUAS-mtdTomato::HA / +
S6B5	w ; VT033006-LexA::p65(JK22C) / LexAop2-QF2-Syntaxin(VK00018) ; MB247-Gal4 QUAS-mtdTomato::HA/+
S14A PV5c1	w 10XUAS-mCD8::RFP(attP18) LexAop2-mCD8::GFP(su(Hw)attP8) / + ; 16C09-p65ADZp(attp40) / + ; 28A10-ZpGdbd(attp2) / +
S14A AV6a1	w 10XUAS-mCD8::RFP(attP18) LexAop2-mCD8::GFP(su(Hw)attP8) / + ;93A02-p65ADZp(attp40) / + ; 44G08-ZpGdbd(attp2) / +

Figure	Genotype
S14B PV5c1	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 16C09-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 28A10-ZpGdbd(attp2)
S14B AV6a1	QUAS-3xHalo(attp3) w / w ; LexAop2-Syb::GFP-P10(VK00037) VT033006-LexA::p65(JK22C) LexAop2-QF2::minSNAP25::HIVNES::Syx(VK00018) / 93A02-p65ADZp(attp40) ; 20XUAS-B3R.PEST(attP2) UAS-B3RT-B2-B3RT-BoNT/A(VK00005) UAS-B3RT-B2-B3RT-BoNT/A(VK00027) / 44G08-ZpGdbd(attp2)

Table S15: **Genotypes of flies used in this study.** Genes in *italics* were present in the experiment but are not relevant to the result. All LexAop2 transgenes have 13 copies of the unitary DNA operator. QUAS constructs have 5 QUAS repeats.

EM identifier (skid)	Name	Partners	Post-Synapses
2685029	AV1 2685030 RJVR ZM	102	179
2664521	AV1a 2664522 FML Plantation	168	542
2659704	AV1a1#1 2659705 FML Duck	244	1207
2684792	AV1a1#2 2684793 Pigeon RJVR FML ZM	192	618
1967862	AV1a2#1 1967863 Pheasant AJES	288	735
1299700	PD2a1#1 1299701 ASB	212	963
2205218	PD2a1#2 1290496 Deirdre ASB	380	1009
1415893	PD2a1#3 1415894 Cu Chulainn ASB	189	456
1454234	PD2a1#4 1454235 Medb ASB	222	650
11547665	PD2a1#5 3516954 Conchobar ASB	286	933
1606113	PD2b1#1 1606114 ASB	241	584
3345012	PD2b1#2 3345012 Cù Sith ASB	188	477
3347813	PD2b1#3 3345012 Ban Sith ASB	198	393
Average		223	673

Table S16: **Summary of connected neurons and post-synapses of AV1a and PD2a1/b1 neurons traced on the EM volume.**